Committee for medicinal products for human use (CHMP)
Minutes of the meeting on 06-09 November 2023
Chair: Harald Enzmann – Vice-Chair: Bruno Sepodes

Health and safety information
In accordance with the Agency’s health and safety policy, delegates were briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in these minutes is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this set of minutes is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the minutes cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

## 1. Introduction 8

1.1. Welcome and declarations of interest of members, alternates and experts ................. 8  
1.2. Adoption of agenda ........................................................................................................ 8  
1.3. Adoption of the minutes .............................................................................................. 8  

## 2. Oral Explanations 9

2.1. Pre-authorisation procedure oral explanations .............................................................. 9  
2.1.1. tofersen - Orphan - EMEA/H/C/005493 ................................................................. 9  
2.2. Re-examination procedure oral explanations ............................................................ 9  
2.2.1. Krazati - adagrasib - EMEA/H/C/006013 .............................................................. 9  
2.3. Post-authorisation procedure oral explanations ......................................................... 9  
2.3.1. Veltassa - patiromer - EMEA/H/C/004180/X/0031/G ............................................ 9  
2.4. Referral procedure oral explanations ..................................................................... 10  

## 3. Initial applications 10

3.1. Initial applications; Opinions ........................................................................................ 10  
3.1.1. Azacitidine Kabi - azacitidine - EMEA/H/C/006154 ................................................. 10  
3.1.2. Naveruclif - paclitaxel - EMEA/H/C/006173 ........................................................ 10  
3.1.3. Omjira - momelotinib - Orphan - EMEA/H/C/005768 ............................................. 11  
3.1.4. Rimmyrah - ranibizumab - EMEA/H/C/006055 ..................................................... 11  
3.1.5. Rystiggo - rozanolixizumab - Orphan - EMEA/H/C/005824 ................................. 12  
3.1.6. Spexotras - trametinib - Orphan - EMEA/H/C/005886 ............................................ 12  
3.1.7. Uzpruvo - ustekinumab - EMEA/H/C/006101 ...................................................... 13  
3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) .............................................................. 13  
3.2.1. polihexanide - Orphan - EMEA/H/C/005858 ....................................................... 13  
3.2.2. exagamgogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763 ......... 14  
3.2.3. Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006052 ......................................................... 14  
3.2.4. cefepime / enmetazobactam - EMEA/H/C/005431 ................................................. 14  
3.2.5. Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006051 .............................................................. 15  
3.2.6. leniolisib - Orphan - EMEA/H/C/005927 .............................................................. 15  
3.2.7. catumaxomab - EMEA/H/C/005697 ..................................................................... 15  
3.2.8. lecanemab - EMEA/H/C/005966 ................................................................. 15  
3.2.9. bevacizumab - EMEA/H/C/005723 ................................................................. 16  
3.2.10. paliperidone - EMEA/H/C/006185 ................................................................. 16  
3.2.11. pomalidomide - EMEA/H/C/006195 ................................................................. 16
3.2.12. tofersen - Orphan - EMEA/H/C/005493 ................................................................. 16
3.2.13. danicopan - PRIME - Orphan - EMEA/H/C/005517 ............................................... 17

3.3. **Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)** ................................................. 17
3.3.1. dasiglucagon - EMEA/H/C/006214 ........................................................................ 17
3.3.2. levetiracetam - EMEA/H/C/006186 ....................................................................... 17
3.3.3. ustekinumab - EMEA/H/C/006221 ....................................................................... 18
3.3.4. nilotinib - EMEA/H/C/006315 ................................................................................ 18
3.3.5. crovalimab - EMEA/H/C/006061 ........................................................................... 18
3.3.6. Respiratory syncytial virus mRNA vaccine – OPEN – EMEA/H/C/006278 ............ 18
3.3.7. teriparatide - EMEA/H/C/005687 .......................................................................... 19
3.3.8. zolbetuximab - Orphan - EMEA/H/C/005868 ......................................................... 19
3.3.9. macitentan / tadalafil - EMEA/H/C/005001 ........................................................... 19

3.4. **Update on on-going initial applications for Centralised procedure** ..................... 19
3.4.1. apadamtase alfa - Orphan - EMEA/H/C/006198 ..................................................... 19
3.4.2. dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009 .............. 20
3.4.3. ustekinumab - EMEA/H/C/006183 ....................................................................... 20
3.4.4. omalizumab - EMEA/H/C/005958 ....................................................................... 20

3.5. **Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004** ................................................................. 20
3.5.1. Krazati - adagrasib - EMEA/H/C/006013 ............................................................... 20

3.6. **Initial applications in the decision-making phase** ............................................. 21

3.7. **Withdrawals of initial marketing authorisation application** ............................... 21
3.7.1. Vijoce - alpelisib - Orphan - EMEA/H/C/005468 ................................................. 21

4. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008** ........................................... 21
4.1. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion** ........................................ 21
4.1.1. Eylea - aflibercept - EMEA/H/C/002392/X/0084/G ........................................... 21
4.1.2. Skyrizi - risankizumab - EMEA/H/C/004759/X/0033 ........................................... 22
4.1.3. Talzenna - talazoparib - EMEA/H/C/004674/X/0015/G ....................................... 22
4.1.4. Tecentriq - atezolizumab - EMEA/H/C/004143/X/0076 ........................................ 23
4.1.5. Veltassa - patiromer - EMEA/H/C/004180/X/0031/G .......................................... 23

4.2. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**  ........................................................................................................... 24
4.2.1. Azacitidine Accord - azacitidine - EMEA/H/C/005147/X/0013 ........................... 24
4.2.2. Uptravi - selexipag - EMEA/H/C/003774/X/0038 ................................................. 24

4.3. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question** ......... 24
4.3.1. Abilify Maintena - aripiprazole - EMEA/H/C/002755/X/0045 ............................ 24
4.3.2. Reagila - cariprazine - EMEA/H/C/002770/X/0033 ................................................................. 25
4.3.3. Spevigo - spesolimab - EMEA/H/C/005874/X/0006/G .................................................... 25
4.3.4. Tepadina - thiotepa - EMEA/H/C/001046/X/0049 ............................................................ 26

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008 ............................................................................ 26

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008 ........................................ 26

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information ........................................................................... 26

5.1.1. Abecma - idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662/II/0031 ............ 26
5.1.2. Aspaveli - pegcetacoplan - Orphan - EMEA/H/C/005553/II/0011 ....................................... 27
5.1.3. Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/II/0023 ........................................ 27
5.1.4. Evkeeza - evinacumab - EMEA/H/C/005449/II/0011 .................................................... 28
5.1.5. Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0043 ....................................................................................... 28
5.1.6. Jardiance - empagliflozin - EMEA/H/C/002677/II/0076 ..................................................... 29
5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0138 ............................................... 29
5.1.8. Metalyse - tenecteplase - EMEA/H/C/000306/II/0070/G .................................................. 30
5.1.9. Mounjaro - tirzepatide - EMEA/H/C/005620/II/0007 .................................................... 30
5.1.10. Moventig - naloxegol - EMEA/H/C/002810/II/0039 .................................................... 31
5.1.11. NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0058 ....................................................................................... 31
5.1.12. Nilemdo - bempedoic acid - EMEA/H/C/004958/II/0031 ............................................. 32
5.1.13. Nustendi - bempedoic acid / ezetimibe - EMEA/H/C/004959/II/0035 ............................ 32
5.1.15. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0022 ............................................... 33
5.1.16. Vabysmo - faricimab - EMEA/H/C/005642/II/0005 ..................................................... 34
5.1.17. Xromi - hydroxycarbamide - EMEA/H/C/004837/II/0019 ........................................... 34

5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ............................................................................ 35

5.2.1. Kisqali - ribociclib - EMEA/H/C/004213/II/0045 ............................................................. 35

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 ........................................ 36

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation ......................................................... 36
6.3. Companion diagnostics - initial consultation ...................................................... 36
6.3.1. in vitro diagnostic medical device - EMEA/H/D/006372 ........................................ 36
6.3.2. in vitro diagnostic medical device - EMEA/H/D/006373 ........................................ 36
6.3.3. in vitro diagnostic medical device - EMEA/H/D/006310 ........................................ 36
6.4. Companion diagnostics – follow-up consultation .............................................. 37

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 37
7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 37

8. Pre-submission issues 37
8.1. Pre-submission issue .............................................................................................. 37
8.1.1. mozafancogene autotemcel – ATMP - Orphan - H0005537 ........................................ 37
8.1.2. vorasidenib - Orphan - H0006284 ........................................................................... 37
8.2. Priority Medicines (PRIME) .................................................................................. 38

9. Post-authorisation issues 38
9.1. Post-authorisation issues .......................................................................................... 38
9.1.1. Arexvy - respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E - EMEA/H/C/006054/II/0002/G ........................................ 38
9.1.2. Bylvay - odevixibat - Orphan - EMEA/H/C/004691/II/0011 ............................... 38
9.1.3. Leqvio– Inclisiran – EMEA/H/C/005333 .............................................................. 39
9.1.5. Pradaxa - dabigatran etexilate - EMEA/H/C/000829/II/0147/G .............................. 39
9.1.6. Remsima - infliximab - EMEA/H/C/002576/II/0133/G ......................................... 40
9.1.7. Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0063, Orphan, ATMP .............. 40
9.1.8. Zynrelef - bupivacaine / meloxicam - EMEA/H/C/005205 ......................................... 41
9.1.9. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan ............................. 41
9.1.10. Pazenir – paclitaxel – EMEA/H/C/004441 ......................................................... 42
9.1.11. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan ..................... 42

10. Referral procedures 42
10.1. Procedure for Centrally Authorised products under Article 20 of Regulation (EC) No 726/2004 ................................................................. 42
10.1.1. Ocaliva - obeticholic acid - EMEA/H/A-20/1531 ................................................. 42
10.1.2. Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065 ................................................................. 43
10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004 43
10.3. Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004 ............... 43
10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC ................................. 43

10.5.1. Havrix - EMEA/H/A-30/1527 ................................................................. 44

10.6.1. Azithromycin containing medicinal products for systemic use – EMEA/H/A-31/1532 ...... 44


10.9. Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003 .............................................................. 45


10.11. Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008 ....................................................... 45

11. Pharmacovigilance issue 46

11.1. Early Notification System .................................................................................. 46

12. Inspections 46

12.1. GMP inspections .............................................................................................. 46

12.2. GCP inspections .............................................................................................. 46

12.3. Pharmacovigilance inspections ........................................................................ 46

12.4. GLP inspections .............................................................................................. 46

13. Innovation Task Force 46

13.1. Minutes of Innovation Task Force .................................................................... 46

13.2. Innovation Task Force briefing meetings ......................................................... 46


13.4. Nanomedicines activities .................................................................................. 47

14. Organisational, regulatory and methodological matters 47

14.1. Mandate and organisation of the CHMP .......................................................... 47

14.1.1. Vote by proxy ............................................................................................... 47

14.1.2. CHMP membership .................................................................................... 47

14.1.3. Guidance on SmPC section 5.1 ................................................................. 47

14.2. Coordination with EMA Scientific Committees ................................................. 47

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC) ............................ 47

14.2.2. Paediatric Committee (PDCO) ................................................................... 48

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups .... 48

14.3.2. Scientific Advice Working Party (SAWP) ................................................................. 48
14.4. Cooperation within the EU regulatory network ....................................................... 48
14.5. Cooperation with International Regulators ......................................................... 48
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee ................................................................. 49
14.7. CHMP work plan .................................................................................................... 49
14.8. Planning and reporting .......................................................................................... 49
14.9. Others .................................................................................................................. 49
14.9.1. CHMP Learnings ................................................................................................. 49

15. Any other business 49
15.1. AOB topic ............................................................................................................ 49

List of participants 50
Explanatory notes 56
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

   The Chairperson opened the meeting by welcoming all participants. The meeting was held in-person.

   In accordance with the Agency’s policy on handling of declarations of interests of scientific Committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the meeting, the Committee Secretariat announced the restricted involvement of some Committee members, alternates and experts for concerned agenda topics.

   Participants were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared. Restrictions applicable to this meeting are captured in the list of participants included in the minutes.

   Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure. All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

1.2. **Adoption of agenda**

   CHMP agenda for 06-09 November 2023.

   The CHMP adopted the agenda.

1.3. **Adoption of the minutes**

   CHMP minutes for 09-12 October 2023.

   The CHMP adopted the minutes for the 09-12 October 2023 plenary.

   Minutes from PReparatory and Organisational Matters (PROM) meeting held on 12 October 2023 and 30 October 2023.

   The CHMP adopted the minutes from the PROM meetings held on 12 October 2023 and 30 October 2023.
2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. tofersen - Orphan - EMEA/H/C/005493

Biogen Netherlands B.V.; treatment of adults with amyotrophic lateral sclerosis (ALS), associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Scope: Oral explanation

**Action**: Oral explanation to be held on 07 November 2023 at 14:00


The CHMP agreed that an oral explanation was not needed at this time.

See 3.2

2.2. Re-examination procedure oral explanations

2.2.1. Krazati - adagrasib - EMEA/H/C/006013

Mirati Therapeutics B.V.; treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation

Scope: Oral explanation

**Action**: Oral explanation to be held on 6 November 2023 at 16:00

New active substance (Article 8(3) of Directive No 2001/83/EC)


An oral explanation was held on 6 November 2023. The presentation by the applicant focused on clinical data.

See 3.5

2.3. Post-authorisation procedure oral explanations

2.3.1. Veltassa - patiromer - EMEA/H/C/004180/X/0031/G

Vifor Fresenius Medical Care Renal Pharma France

Scope: "Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 12 to 17 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer for oral
suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 6.5 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 2.3 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes.”

Possible oral explanation

**Action:** Possible oral explanation to be held on 08 November 2023 at 16:00


The CHMP agreed that an oral explanation was not needed at this time.

See 4.1

### 2.4. Referral procedure oral explanations

No items

### 3. Initial applications

#### 3.1. Initial applications; Opinions

##### 3.1.1. Azacitidine Kabi - azacitidine - EMEA/H/C/006154

Fresenius Kabi Deutschland GmbH; Treatment of myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML)

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Vidaza


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

##### 3.1.2. Naveruclif - paclitaxel - EMEA/H/C/006173

Accord Healthcare S.L.U.; treatment of metastatic breast cancer
Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Abraxane


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.3. **Omjjara - momelotinib - Orphan - EMEA/H/C/005768**

Glaxosmithkline Trading Services Limited; treatment of disease-related splenomegaly or symptoms and anaemia

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that momelotinib is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 07 November 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.4. **Rimmyrah - ranibizumab - EMEA/H/C/006055**

QILU PHARMA SPAIN S.L.; treatment of neovascular age-related macular degeneration (AMD)

Scope: Opinion
**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 03 November 2023.

The summary of opinion was circulated for information.

---

3.1.5. **Rystiggo - rozanolixizumab - Orphan - EMEA/H/C/005824**

UCB Pharma; Treatment of generalised myasthenia gravis (gMG)

Scope: Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that rozanolixizumab is a new active substance, as claimed by the applicant.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 07 November 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

---

3.1.6. **Spexotras - trametinib - Orphan - EMEA/H/C/005886**

Novartis Europharm Limited; Treatment of paediatric patients aged 1 year and older with glioma

Scope: Opinion

**Action:** For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC)

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 06 November 2023.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

3.1.7. **Uzpruvo - ustekinumab - EMEA/H/C/006101**

STADA Arzneimittel AG; treatment of plaque psoriasis, arthritis psoriatic, Crohn’s Disease and ulcerative colitis

**Scope:** Opinion

**Action:** For adoption

Similar biological application (Article 10(4) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.2. **Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)**

3.2.1. **polihexanide - Orphan - EMEA/H/C/005858**

SIFI SPA; treatment of acanthamoeba keratitis

**Scope:** List of outstanding issues

**Action:** For adoption

List of Questions adopted on 15.09.2022.

The Committee was reminded of the status of this application and its remaining outstanding issues.
The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.2. exagamglogene autotemcel - PRIME - Orphan - ATMP - EMEA/H/C/005763

Vertex Pharmaceuticals (Ireland) Limited; treatment of transfusion-dependent β-thalassemia and sickle cell disease

**Scope:** List of outstanding issues

**Action:** For information


The CHMP was updated on the discussions at the CAT. The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee endorsed the 2nd list of outstanding issues with a specific timetable as adopted by CAT.

### 3.2.3. Zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006052

active immunisation for the prevention of disease caused by the influenza A virus H5N1 subtype contained in the vaccine

**Scope:** List of outstanding issues

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.4. cefepime / enmetazobactam - EMEA/H/C/005431

treatment of: 1) complicated urinary tract infections (including pyelonephritis); 2) hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP); 3) patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above and 4) infections due to aerobic Gram-negative organisms in adults with limited treatment options

**Scope:** List of outstanding issues

**Action:** For adoption

List of Questions adopted on 25.05.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.
3.2.5. Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures) - EMEA/H/C/006051

prophylaxis of influenza
Scope: List of outstanding issues

**Action**: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.6. leniolisib - Orphan - EMEA/H/C/005927

Pharming Technologies B.V.; Treatment of activated phosphoinositide 3-kinase delta syndrome (APDS)

Scope: List of outstanding issues

**Action**: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2\(^{nd}\) list of outstanding issues with a specific timetable.

3.2.7. catumaxomab - EMEA/H/C/005697

indicated for the treatment of malignant ascites
Scope: List of outstanding issues

**Action**: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. lecanemab - EMEA/H/C/005966

a disease modifying treatment in adult patients with Mild Cognitive Impairment due to Alzheimer’s disease and Mild Alzheimer’s disease (Early Alzheimer’s disease)

Scope: List of outstanding issues

**Action**: For adoption

List of Questions adopted on 25.05.2023.

The CHMP noted the third-party interventions.
The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

The CHMP agreed to consult a SAG and adopted a list of questions to these experts.

3.2.9. bevacizumab - EMEA/H/C/005723

Treatment of neovascular (wet) age-related macular degeneration (nAMD).

Scope: List of outstanding issues

Action: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. paliperidone - EMEA/H/C/006185

Treatment of schizophrenia

Scope: List of outstanding issues

Action: For adoption

List of Questions adopted on 25.05.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.11. pomalidomide - EMEA/H/C/006195

in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma (MM)

Scope: List of outstanding issues

Action: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.12. tofersen - Orphan - EMEA/H/C/005493

Biogen Netherlands B.V.; treatment of adults with amyotrophic lateral sclerosis (ALS),
associated with a mutation in the superoxide dismutase 1 (SOD1) gene.

Scope: List of outstanding issues

**Action:** For adoption


See 2.1

The CHMP agreed that an oral explanation was not needed at this time.

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues with a specific timetable.

### 3.2.13. danicopan - PRIME - Orphan - EMEA/H/C/005517

Alexion Europe; Treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria

Scope: List of outstanding issues

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

#### 3.3.1. dasiglucagon - EMEA/H/C/006214

treatment of severe hypoglycemia in patients with diabetes

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

#### 3.3.2. levetiracetam - EMEA/H/C/006186

treatment of partial onset seizures

Scope: List of questions

**Action:** For adoption

The Committee discussed the issues identified in this application.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.3. ustekinumab - EMEA/H/C/006221

- treatment of active plaque psoriasis, Crohn’s disease, active ulcerative colitis and active psoriatic arthritis, treatment of plaque psoriasis
- Scope: List of questions
- **Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.4. nilotinib - EMEA/H/C/006315

- treatment of Philadelphia chromosome positive chronic myelogenous leukaemia (CML)
- Scope: List of questions
- **Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.5. crovalimab - EMEA/H/C/006061

- treatment of paroxysmal nocturnal haemoglobinuria
- Scope: List of questions
- **Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.6. Respiratory syncytial virus mRNA vaccine – OPEN – EMEA/H/C/006278

- Prevention of lower respiratory tract disease (LRTD) and acute respiratory disease (ARD) caused by respiratory syncytial virus (RSV)
- Scope: List of questions
- **Action:** For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.
3.3.7. **teriparatide - EMEA/H/C/005687**

- treatment of osteoporosis
- **Scope**: List of questions
- **Action**: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.8. **zolbetuximab - Orphan - EMEA/H/C/005868**

- Astellas Pharma Europe B.V.; treatment of locally advanced unresectable or metastatic HER2 negative gastric or gastro-oesophageal junction (GEJ) adenocarcinoma
- **Scope**: List of questions
- **Action**: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.3.9. **macitentan / tadalafil - EMEA/H/C/005001**

- treatment of pulmonary arterial hypertension (PAH) in adults patients
- **Scope**: List of questions
- **Action**: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

3.4. **Update on on-going initial applications for Centralised procedure**

3.4.1. **apadamtase alfa - Orphan - EMEA/H/C/006198**

- Takeda Manufacturing Austria AG; treatment of congenital thrombotic thrombocytopenic purpura (cTTP) due to ADAMTS13 deficiency
- **Scope**: Letter by the applicant dated 24.10.2023 requesting an extension to the clock stop to respond to the list of questions adopted in September 2023.
- **Action**: For adoption


The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2023.
3.4.2. dantrolene sodium, hemiheptahydrate - Orphan - EMEA/H/C/006009

Norgine B.V.; treatment of malignant hyperthermia (including suspected cases)
Scope: Letter by the applicant dated 30.10.2023 requesting an extension to the clock stop to respond to the list of outstanding issues adopted in June 2023.

Action: For adoption
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues adopted in June 2023.

3.4.3. ustekinumab - EMEA/H/C/006183

treatment of Crohn’s disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)
Scope: BMWP and MWP consultation
The CHMP agreed to consult the BMWP and MWP and adopted a list of questions to these working parties.

3.4.4. omalizumab - EMEA/H/C/005958

treatment of asthma
Scope: Letter by the applicant dated 08.11.2023 requesting an extension to the clock stop to respond to the list of questions adopted in September 2023.
The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of questions adopted in September 2023.

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Krazati - adagrasib - EMEA/H/C/006013

Mirati Therapeutics B.V.; treatment of patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation
Scope: Opinion
Action: For adoption
New active substance (Article 8(3) of Directive No 2001/83/EC)
Opinion adopted on 20.07.2023. List of Outstanding Issues adopted on 25.05.2023,
See 2.2
An oral explanation was held on 6 November 2023. The presentation by the applicant focused on clinical data.

The CHMP adopted a positive opinion by majority (28 positive out of 32 votes) recommending the granting of a conditional marketing authorisation together with the CHMP assessment report and translation timetable.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The divergent position (Peter Mol, Jan Mueller-Berghaus, Robert Porszasz, Martina Weise) was appended to the opinion.

The question-and-answer document was circulated for information.

### 3.6. Initial applications in the decision-making phase

No items

### 3.7. Withdrawals of initial marketing authorisation application

3.7.1. **Vijoice - alpelisib - Orphan - EMEA/H/C/005468**

Novartis Europharm Limited; treatment of patients with severe manifestations of PIK3CA-related overgrowth spectrum

Scope: Withdrawal of initial marketing authorisation application

New active substance (Article 8(3) of Directive No 2001/83/EC)


The CHMP noted the withdrawal of marketing authorisation application.

### 4. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

4.1. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion**

4.1.1. **Eylea - aflibercept - EMEA/H/C/002392/X/0084/G**

Bayer AG

Rapporteur: Jean-Michel Race, PRAC Rapporteur: Nathalie Gault

Scope: “Extension application to add a new strength of Aflibercept 114.3 mg/ml solution for injection (in a vial), to be indicated in adults for the (1) treatment of neovascular (wet) age-related macular degeneration (nAMD) and (2) visual impairment due to diabetic macular oedema (DME), grouped with a type II variation (B.II.g.2) to introduce a post-approval change management protocol to add a new presentation for Aflibercept solution 114.3...
mg/ml in a single-use pre-filled syringe for intravitreal injection.”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

### 4.1.2. Skyrizi - risankizumab - EMEA/H/C/004759/X/0033

**AbbVie Deutschland GmbH & Co. KG**

**Rapporteur:** Finbarr Leacy

**Scope:** “Extension application to add a new strength of 90 mg solution for injection in pre-filled syringe, indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

### 4.1.3. Talzenna - talazoparib - EMEA/H/C/004674/X/0015/G

**Pfizer Europe MA EEIG**

**Rapporteur:** Filip Josephson, Co-Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Ana Sofia Diniz Martins

**Scope:** "Extension application for Talzenna to introduce a new strength of 0.1 mg hard capsules, grouped with a type II variation (C.I.6.a) in order to extend the indication for Talzenna in combination with enzalutamide for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC), based on final results from study C3441021 (TALAPRO-2) as well as supplemental data from study C3441006 (TALAPRO-1). Study C3441021 (TALAPRO-2) is a randomized, double-blind, placebo-controlled, phase 3 study of talazoparib in combination with enzalutamide in mCRPC, while study C3441006 (TALAPRO-1) is a phase 2, open-label, response rate study of talazoparib in men with DNA repair defects and mCRPC who previously received taxane-based chemotherapy and progressed on at least one novel hormonal agent. As a consequence, sections 1, 2, 3, 4.1, 4.2, 4.5, 4.7, 4.8, 5.1, 5.2, 6.1, 6.5 and 8 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 1.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”
**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

**4.1.4. Tecentriq - atezolizumab - EMEA/H/C/004143/X/0076**

Roche Registration GmbH

Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (1875 mg) and new route of administration (subcutaneous use). The RMP (version 24.0) is updated in accordance."

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

**4.1.5. Veltassa - patiromer - EMEA/H/C/004180/X/0031/G**

Vifor Fresenius Medical Care Renal Pharma France

Rapporteur: Jayne Crowe, PRAC Rapporteur: Kirsti Villikka

Scope: "Extension application to introduce a new strength (1 g powder for oral suspension), grouped with a type II variation (C.I.6.a) in order to extend the indication to include treatment of population from 12 to 17 years old for Veltassa based on final results from paediatric study RLY5016-206P (EMERALD); this is a phase 2, open-label, multiple dose study to evaluate the pharmacodynamic effects, safety, and tolerability of patiromer for oral suspension in children and adolescents 2 to less than 18 years of age with chronic kidney disease and hyperkalaemia. As a consequence, sections 1, 2, 4.1, 4.2, 4.4, 4.5, 4.8, 4.9, 5.1 and 6.5 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 2.3 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce editorial changes."

**Action:** For adoption


See 2.3

The CHMP agreed that an oral explanation was not needed at this time.
The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

4.2. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**

4.2.1. **Azacitidine Accord - azacitidine - EMEA/H/C/005147/X/0013**

Accord Healthcare S.L.U.

Rapporteur: Hrefna Gudmundsdottir, PRAC Rapporteur: Menno van der Elst

Scope: "Extension application to introduce a new pharmaceutical form associated with a new strength (10 mg/ml powder for solution for infusion) and a new route of administration (intravenous use). The RMP version 2 is updated in accordance."

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues relating to quality and clinical aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

4.2.2. **Uptravi - selexipag - EMEA/H/C/003774/X/0038**

Janssen-Cilag International N.V.

Rapporteur: Martina Weise, PRAC Rapporteur: Nathalie Gault

Scope: "Extension application to add a new strength of 100 µg film-coated tablets in HDPE bottle. The RMP (version 10.1) is updated in accordance."

**Action:** For adoption

List of Questions adopted on 22.06.2023.

The Committee was reminded of the status of this application and its remaining outstanding issues relating to quality aspects.

The Committee adopted a list of outstanding issues with a specific timetable.

4.3. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question**

4.3.1. **Abilify Maintena - aripiprazole - EMEA/H/C/002755/X/0045**

Otsuka Pharmaceutical Netherlands B.V.
Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ulla Wändel Liminga

Scope: “Extension application to introduce a new pharmaceutical form associated with two new strengths (720 and 960 mg Prolonged-release suspension for injection). The RMP (version 12.1) is updated in accordance.”

Action: For adoption

The Committee discussed the issues identified in this application relating to quality aspects and the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Reagila - cariprazine - EMEA/H/C/002770/X/0033

Gedeon Richter Plc.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: “Extension application to introduce a new pharmaceutical form (orodispersible tablets). The RMP (version 3.0) is updated in accordance.”

Action: For adoption

The Committee discussed the issues identified in this application relating to quality and clinical aspects as well as the RMP.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Spevigo - spesolimab - EMEA/H/C/005874/X/0006/G

Boehringer Ingelheim International GmbH

Rapporteur: Kristina Dunder, Co-Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Nathalie Gault

Scope: “Extension application to introduce a new pharmaceutical form (solution for injection) associated with a new strength (150 mg) and new route of administration (subcutaneous use), for the prevention of generalised pustular psoriasis (GPP) flares in adults and adolescents from 12 years of age.

This line extension is grouped with a type II variation (C.I.6.a) to extend the indication for Spevigo 450 mg concentrate for solution for infusion to include treatment of generalised pustular psoriasis (GPP) flares in adolescents (from 12 years of age), based on final results from study 1368-0027 (Effisayil 2) and extrapolation; this is a multi-center, randomized, parallel group, double blind, placebo controlled, phase IIb dose-finding study to evaluate efficacy and safety of BI 655130 (spesolimab) compared to placebo in preventing GPP flares in patients with history of GPP. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Annex II and Package Leaflet are updated in accordance. Version 2.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce editorial changes to the PI and update the list of local representatives in the Package Leaflet.”

Action: For adoption
The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.4. Tepadina - thiotepa - EMEA/H/C/001046/X/0049

ADIENNE S.r.l. S.U.
Rapporteur: Alexandre Moreau
Scope: “Extension application to add a new strength (200 mg powder and solvent for solution for infusion).”

Action: For adoption

The Committee discussed the issues identified in this application relating to quality and non-clinical aspects.
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items

5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Abecma - idecabtagene vicleucel - Orphan - ATMP - EMEA/H/C/004662/II/0031

Bristol-Myers Squibb Pharma EEIG
Scope: “Extension of indication to include treatment of adult patients with relapsed and refractory multiple myeloma (RRMM) who have received at least two prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD-38 antibody and have demonstrated disease progression on the last therapy for Abecma (idecabtagene
vicleucel, ide-cel), based on results from study BB2121-MM-003 (MM-003, KarMMa-3). This is a Phase 3, multicentre, randomised, open-label study to compare the efficacy and safety of ide-cel versus standard regimens in subjects with RRMM. As a consequence, sections 2.1, 2.2, 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2, 6.3, 6.4 and 6.6 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 3.0 of the RMP has also been submitted. Furthermore, the PI is brought in line with the Guideline on core SmPC, Labelling and Package Leaflet for advanced therapy medicinal products (ATMPs) containing genetically modified cells.”. Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**Action**: For adoption

Request for Supplementary Information adopted on 16.06.2023.

The CHMP was updated on discussions at CAT. The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee endorsed the 2nd request for supplementary information with a specific timetable as adopted by CAT.

### 5.1.2. Aspaveli - pegcetacoplan - Orphan - EMEA/H/C/005553/II/0011

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Alexandre Moreau, Co-Rapporteur: Selma Arapovic Dzakula, PRAC Rapporteur: Kimmo Jaakkola

Scope: “Extension of indication to include treatment of adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) not previously treated with a complement inhibitor for Aspaveli, based on final results from study APL2-308. This is a Phase III, randomized, open-label, comparator-controlled study that enrolled adult patients with PNH who had not been treated with a complement inhibitor. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted.”

**Action**: For adoption


The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

### 5.1.3. Ayvakyt - avapritinib - Orphan - EMEA/H/C/005208/II/0023

Blueprint Medicines (Netherlands) B.V.

Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst

Scope: “Extension of indication to include treatment of adult patients with indolent systemic mastocytosis (ISM) for avapritinib based on results from the pivotal part of study BLU-285-2203 (PIONEER), this is a 3-part, randomized, double-blind, placebo-controlled, Phase 2 study to evaluate safety and efficacy of avapritinib (BLU-285) in indolent and smoldering systemic mastocytosis with symptoms inadequately controlled with standard therapy. As a
consequence, sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 4.9, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.4 of the RMP has also been submitted.”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.4. Evkeeza - evinacumab - EMEA/H/C/005449/II/0011

**Ultragenyx Germany GmbH**

**Rapporteur:** Patrick Vrijlandt, **Co-Rapporteur:** Alar Irs, **PRAC Rapporteur:** Mari Thorn

**Scope:** "Extension of indication to include the treatment of paediatric patients with homozygous familial hypercholesterolaemia (HoFH) aged 5 years and older for EVKEEZA, based on interim results from study R1500-CL-17100, as well as supportive information from an updated interim analysis of study R1500-CL-1719, and an extrapolation analysis (including population PK, population PK/PD, and simulation analyses). R1500-CL-17100 is an ongoing multicentre, three-part, single-arm, open-label study evaluating the efficacy, safety, and tolerability of evinacumab in paediatric patients aged ≥ 5 to 11 years with HoFH. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Annex II and the Package Leaflet are updated in accordance. Version 1.2 of the RMP has also been submitted. In addition, the marketing authorisation holder took the opportunity to introduce minor editorial changes to the PI. Furthermore, the PI is brought in line with the latest QRD template version 10.3.”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.5. Fluad Tetra - influenza vaccine (surface antigen, inactivated, adjuvanted) - EMEA/H/C/004993/II/0043

**Seqirus Netherlands B.V.**

**Rapporteur:** Sol Ruiz, **PRAC Rapporteur:** Jean-Michel Dogné

**Scope:** "Extension of indication to include adults 50 years of age and older for Fluad Tetra, based on final results from study V118_23; this is a phase 3, randomized, observer-blind, controlled, multicenter, clinical study to evaluate immunogenicity and safety of an MF59-
adjuvanted quadrivalent subunit inactivated influenza vaccine in comparison with a licensed quadrivalent influenza vaccine, in adults 50 to 64 years of age. As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Labelling and Package Leaflet are updated in accordance. Version 3.0 of the RMP has also been approved. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI. The variation leads to amendments to the Summary of Product Characteristics, Labelling and Package Leaflet and to the Risk Management Plan (RMP).”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.6. Jardiance - empagliflozin - EMEA/H/C/002677/II/0076

Boehringer Ingelheim International GmbH

Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Maria del Pilar Rayon

Scope: “Extension of indication for Jardiance to include treatment of children aged 10 years and above with type 2 diabetes based on results from study DINAMO 1218-0091; this is a double-blind, randomised, placebo-controlled, parallel group trial to evaluate the efficacy and safety of empagliflozin and linagliptin over 26 weeks, with a double-blind active treatment safety extension period up to 52 weeks, in children and adolescents with type 2 diabetes mellitus. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the MAH took the opportunity to implement minor editorial changes in the product information. Version 21.1 of the RMP has also been submitted.

The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet and to the Risk Management Plan (RMP).”

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The CHMP noted the letter of recommendation dated 16 October 2023.

The summary of opinion was circulated for information.

### 5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0138

Merck Sharp & Dohme B.V.

Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst
Committee for medicinal products for human use (CHMP)

Scope: "Extension of indication to include Keytruda in combination with gemcitabine and cisplatin for the first-line treatment of locally advanced unresectable or metastatic biliary tract carcinoma in adults, based on final results from study KEYNOTE-966; this is a Phase 3 randomized, double blind study of Pembrolizumab plus Gemcitabine/Cisplatin versus Placebo plus Gemcitabine/Cisplatin as first-line therapy in participants with advanced and/or unresectable biliary tract carcinoma. As a consequence, sections 4.1, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 41.0 of the RMP has also been submitted."

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

The CHMP adopted the similarity assessment report.

---

5.1.8. **Metalyse - tenecteplase - EMEA/H/C/000306/II/0070/G**

Boehringer Ingelheim International GmbH

Rapporteur: Martina Weise

Scope: "Grouped application consisting of:
C.1.6.a (Type II): To add the new therapeutic indication Acute Ischemic Stroke (AIS) for the new 25 mg presentation. Consequently, a separate SmPC and Package Leaflet are provided for the 25 mg presentation with the new indication. In addition, the MAH took the opportunity to implement editorial changes and minor updates to the PI of Metalyse 40 mg (8,000 U) and 50 mg (10,000 U).
B.II.e.5.c (Type II): To add the new 25 mg presentation for the sterile parenteral biological medicinal product Metalyse (tenecteplase) powder and solvent for solution for injection.
B.II.b.3.a
B.II.e.1.b.2"

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

---

5.1.9. **Mounjaro - tirzepatide - EMEA/H/C/005620/II/0007**

Eli Lilly Nederland B.V.

Rapporteur: Martina Weise, Co-Rapporteur: Kristina Dunder, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include chronic weight management, including weight loss and weight maintenance, for Mounjaro, as an adjunct to a reduced-calorie diet and increased physical activity in adults with an initial body mass index (BMI) of ≥ 30 kg/m²"
(obesity), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbid condition, based on a global, pivotal phase 3 study I8F-MC-GPHK (SURMOUNT-1) and five supportive phase 3 studies (SURPASS-1 to -5) in participants with T2DM and BMI ≥ 27 kg/m². SURMOUNT-1 is a phase 3, randomized, double-blind, placebo-controlled trial to investigate the efficacy and safety of tirzepatide once weekly in participants without type 2 diabetes who have obesity or are overweight with weight related comorbidities. As a consequence, sections 4.1, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.10. Moventig - naloxegol - EMEA/H/C/002810/II/0039

Kyowa Kirin Holdings B.V.

Rapporteur: Christophe Focke, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Rhea Fitzgerald

**Scope:** "Update of sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update information regarding the use of naloxegol in OIC patients with cancer-related pain based on real-world data from non-interventional studies (NACASY, KNYOAL, and MOVE studies), post-marketing data and literature. The Package Leaflet is updated accordingly. The RMP version 8 has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

**Action:** For adoption


The committee noted that the MAH decided not to pursue the extension to the therapeutic indication and the implementation of real-world data in 5.1 of the SmPC.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

### 5.1.11. NexoBrid - concentrate of proteolytic enzymes enriched in bromelain - EMEA/H/C/002246/II/0058

MediWound Germany GmbH

Rapporteur: Janet Koenig, PRAC Rapporteur: Martin Huber
Scope: "Extension of current indication for removal of eschar in adults with deep partial- and full-thickness thermal burns to the paediatric population for NexoBrid based on interim results from study MW2012-01-01 (CIDS study), listed as study MW2012-01-01 is a 3-stage, multi-centre, multi-national, randomised, controlled, open label, 2 arm study aiming to demonstrate the superiority of NexoBrid treatment over SOC treatment in paediatric patients (aged 0 to 18 years) with deep partial thickness (DPT) and full thickness (FT) thermal burns of 1% to 30% of total body surface area (TBSA).

As a consequence, sections 4.1, 4.2, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 9 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 22.06.2023, 15.12.2022.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

### 5.1.12. Nilemdo - bempedoic acid - EMEA/H/C/004958/II/0031

Daiichi Sankyo Europe GmbH

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk, based on results from study 1002-043 (CLEAR). CLEAR Outcomes Study is a phase 3 multi-centre randomised, double-blind, placebo-controlled study to evaluate whether long-term treatment with bempedoic acid reduces the risk of major adverse cardiovascular events (MACE) in patients with, or at high risk for, cardiovascular disease who are statin intolerant.

As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated accordingly. Version 4.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor formatting changes to the PI. As part of the application, the MAH is requesting a 1-year extension of the market protection."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.13. Nustendi - bempedoic acid / ezetimibe - EMEA/H/C/004959/II/0035

Daiichi Sankyo Europe GmbH

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Kimmo Jaakkola

Scope: "Extension of indication to include treatment of adults with established or at high risk for atherosclerotic cardiovascular disease to reduce cardiovascular risk for Nustendi,
based on results from study 1002-043, known as the CLEAR [Cholesterol Lowering via Bempeido Acid, an ATP citrate lyase (ACL) Inhibiting Regimen] Outcomes Trial; this is a Phase 3, randomized, double-blind, placebo-controlled study to assess the effects of bempeidoic acid (ETC-1002) on the occurrence of major cardiovascular events in patients with, or at high risk for, cardiovascular disease who are statin intolerant; As a consequence, sections 4.1, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.0 of the RMP has also been submitted. As part of the application the MAH is requesting a 1-year extension of the market protection.

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.14. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0021

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication to include the treatment of adults and adolescents 12 years and older with advanced RET fusion-positive thyroid cancer in the first-line setting for Retsevmo based on interim data from studies LIBRETTO-001 (LOXO-RET-17001) and LIBRETTO-121; LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in patients with RET-altered advanced solid tumours. LIBRETTO-121 is a Phase 1/2 study of selpercatinib in paediatric patients with advanced RET-altered solid or primary central nervous system tumours. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.2 of the RMP has also been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a 3rd request for supplementary information with a specific timetable.

### 5.1.15. Retsevmo - selpercatinib - EMEA/H/C/005375/II/0022

Eli Lilly Nederland B.V.

Rapporteur: Alexandre Moreau, Co-Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur: Menno van der Elst

Scope: "Extension of indication for Retsevmo to include the treatment of adults with advanced or metastatic RET fusion-positive solid tumours with disease progression on or after prior systemic therapies or who have no satisfactory therapeutic options, based on interim data from study LIBRETTO-001 (LOXO-RET-17001); LIBRETTO-001 is an open-label, multicentre, global Phase 1/2 study of selpercatinib in adult and adolescent patients with advanced RET-altered tumours. As a consequence, sections 4.1, 4.2 and 5.1 of the..."
SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to implement editorial changes to the SmPC."

**Action:** For adoption

Request for Supplementary Information adopted on 20.07.2023, 30.03.2023.

The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted a 3rd request for supplementary information with a specific timetable.

5.1.16. **Vabysmo - faricimab - EMEA/H/C/005642/II/0005**

Roche Registration GmbH

Rapporteur: Jayne Crowe, PRAC Rapporteur: Ana Sofia Diniz Martins

Scope: "Extension of indication to include treatment of adult patients with visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) for Vabysmo, based on results from the two phase 3 studies: GR41984 (BALATON) in patients with branch retinal vein occlusion (BRVO) and GR41986 (COMINO) in patients with central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO). These are global, multicenter, randomized, double-masked, active comparator-controlled, parallel-group, 2-part studies evaluating the efficacy, safety, and PK of faricimab. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC have been updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to introduce minor changes to the PI."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted a request for supplementary information with a specific timetable.

5.1.17. **Xromi - hydroxycarbamide - EMEA/H/C/004837/II/0019**

Nova Laboratories Ireland Limited

Rapporteur: Anastasia Mountaki, Co-Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Jo Robays

Scope: "Extension of indication to include the prevention of vaso-occlusive complications of sickle cell disease in children from 6 months to 2 years of age for Xromi, based on final results from the paediatric study INV543, listed as a category 3 study in the RMP; this is a single-arm, open-label, multi-center study in children with sickle cell anaemia over 6 months of age. As a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 4.1 of the RMP has also been submitted."

**Action:** For adoption


The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted a 2nd request for supplementary information with a specific timetable.
timetable.

5.1.18.  WS2552
Ongentys - opicapone - EMEA/H/C/002790/WS2552/0060
Ontilyv - opicapone - EMEA/H/C/005782/WS2552/0015

Bial Portela & Companhia S.A.
Lead Rapporteur: Martina Weise, PRAC Rapporteur: Maria del Pilar Rayon

Scope: "Extension of indication to include treatment of signs and symptoms of Parkinson’s Disease for Ongentys/Ontilyv, based on final results from study BIA-91067-303; this is a pivotal Phase III, multicentre, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of opicapone in patients with early idiopathic Parkinson’s Disease receiving treatment with L-DOPA plus a DDCI, and who are without signs of any motor complication. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 6.0 of the RMP has also been submitted (only applicable to Ongentys) to reflect the changes made upon approval of the informed consent application, to keep consistency between the eCTD lifecycles of the two marketing authorisations (Ongentys and Ontilyv). Furthermore, the PI is brought in line with the latest QRD template version 10.3. In addition, as part of the application the MAH is requesting a 1-year extension of the market protection." , Request for 1 year of market protection (Article 14(11) of Regulation (EC) 726/2004)

Action: For adoption

The Committee discussed the issues identified in this application relating to clinical aspects and the request for 1 year of market protection.

The Committee adopted a request for supplementary information with a specific timetable.

5.2.  Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

5.2.1.  Kisqali - ribociclib - EMEA/H/C/004213/II/0045

Novartis Europharm Limited
Rapporteur: Filip Josephson, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "Extension of indication to include the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, Stage II or Stage III early breast cancer, irrespective of nodal status, in combination with an AI for Kisqali based on study CLEE011O12301C (NATALEE); This is a global, Phase III, multicenter, randomised, open-label trial to evaluate efficacy and safety of ribociclib with ET versus ET alone as adjuvant treatment in patients with HR-positive, HER2-negative, early breast cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 5.3 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 8.0 of the RMP has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.”

Third-party intervention.
Committee for medicinal products for human use (CHMP)

5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008

No items

6. Medical devices

6.1. Ancillary medicinal substances - initial consultation

No items

6.2. Ancillary medicinal substances – post-consultation update

No items

6.3. Companion diagnostics - initial consultation

6.3.1. in vitro diagnostic medical device - EMEA/H/D/006372

next generation sequencing (NGS) assay for tumour mutation profiling
Scope: Request for supplementary information
Action: For adoption
The Committee discussed the issues identified in this application relating to clinical aspects.
The Committee adopted a request for supplementary information with a specific timetable.

6.3.2. in vitro diagnostic medical device - EMEA/H/D/006373

detection of PD-L1 protein
Scope: Opinion
Action: For adoption
The Committee discussed the issues identified in this application relating to clinical aspects.
The Committee adopted a 2nd request for supplementary information with a specific timetable.

6.3.3. in vitro diagnostic medical device - EMEA/H/D/006310

immunohistochemical assay utilising an anti-PD-L1 monoclonal primary antibody
Scope: Opinion

**Action:** For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report.

### 6.4. Companion diagnostics – follow-up consultation

No items

### 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

#### 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

### 8. Pre-submission issues

#### 8.1. Pre-submission issue

**8.1.1. mozafancogene autotemcel – ATMP - Orphan - H0005537**

Rocket Pharmaceuticals B.V., Fanconi anemia Type A

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

**Action:** For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.

**8.1.2. vorasidenib - Orphan - H0006284**

Les Laboratoires Servier, Treatment of patients with residual/recurrent Grade 2 glioma harbouring an isocitrate dehydrogenase 1 (IDH1) mutation or isocitrate dehydrogenase 2 (IDH2) mutation who have undergone surgery as their only treatment

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

**Action:** For adoption
The CHMP agreed to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.

8.2. **Priority Medicines (PRIME)**

Information related to priority medicines cannot be released at present time as these contain commercially confidential information.

The CHMP adopted the recommendations for PRIME eligibility.

The individual outcomes are listed in the PRIME Monthly Report on the EMA website, in the PRIME homepage, under Outcome of eligibility section.

9. **Post-authorisation issues**

9.1. **Post-authorisation issues**

9.1.1. **Arexvy - respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E - EMEA/H/C/006054/II/0002/G**

GlaxoSmithKline Biologicals S.A.

Rapporteur: Patrick Vrijlandt

Scope: "Update of section 4.5 of the SmPC in order to update information on the co-administration with inactivated seasonal quadrivalent influenza vaccines: with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV) based on final results from studies RSV OA=ADJ-008 and RSV OA=ADJ-017. These are Phase III studies intended to evaluate the immune response, safety and reactogenicity of Arexvy when co-administered with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV), respectively."

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

9.1.2. **Bylvay - odevixibat - Orphan - EMEA/H/C/004691/II/0011**

Albireo

Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Jayne Crowe

Scope: "Extension of indication to include the treatment of cholestatic pruritus in Alagille syndrome (ALGS) in patients aged 6 months or older for Bylvay, based on final results from study A4250-012 and interim results from study A4250-015. Study A4250-012 is a 24-week, randomised, double-blind, placebo-controlled Phase III study conducted in 52 patients with a genetically confirmed diagnosis of ALGS and presence of pruritus and high serum bile acid levels at baseline. Study A4250-015 is an ongoing 72-week open-label..."
extension trial for patients who completed study A4250-012 and evaluates the long-term safety and efficacy of Bylvay in patients with ALGS. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC and Annex II of the Marketing Authorisation are updated. The Package Leaflet is updated in accordance. Version 2.4 of the RMP has also been submitted. The variation leads to amendments to the Summary of Product Characteristics and Package Leaflet, Annex II and to the Risk Management Plan (RMP).”

Withdrawal of Type-II variation application

**Action:** For information


The CHMP noted the withdrawal of the Type-II variation application.

9.1.3. **Leqvio– Inclisiran – EMEA/H/C/005333**

Novartis Europharm Limited; treatment for primary hypercholesterolaemia or mixed dyslipidaemia

Rapporteur: Martina Weise, Co-Rapporteur: Ewa Balkowiec Iskra

Scope: DHPC and communication plan

**Action:** For adoption

The CHMP adopted the DHPC and communication plan.

9.1.4. **Nuvaxovid - Covid-19 Vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0058/G**

Novavax CZ, a.s.

Rapporteur: Patrick Vrijlandt

Scope: quality

Positive opinion was adopted via written procedure on 31.10.2023.

**Action:** For information

The CHMP noted the positive opinion, which was adopted by consensus on 31.10.2023 via written procedure.

9.1.5. **Pradaxa - dabigatran etexilate - EMEA/H/C/000829/II/0147/G**

Boehringer Ingelheim International GmbH

Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marie Louise Schougaard Christiansen

Scope: "A Grouped application consisting of:

C.I.7.a (type IB): to delete the pharmaceutical form "powder and solvent for oral solution, 6.25 mg/ml", as agreed in procedure EMEA/H/C/000829/II/0144.

C.I.4 (type II): Update of section 4.1 of the SmPC in order to modify the indication following the deletion of the powder and solvent for oral solution; the Package Leaflet is updated
accordingly. The RMP version 41.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet.”

**Action:** For adoption

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

The summary of opinion was circulated for information.

## 9.1.6. Remsima - infliximab - EMEA/H/C/002576/II/0133/G

Celltrion Healthcare Hungary Kft.

Rapporteur: Outi Mäki-Ikola, Co-Rapporteur: Kristina Dunder

Scope: “Grouped application comprising three type II variations (C.I.4) as follows:
- Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (Crohn’s disease), listed as a category 3 study in the RMP; study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Modestly to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease.
- Update of sections 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (> 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study).

The RMP version 16.1 has also been submitted. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI.”

**Action:** For adoption

The Committee discussed the issues identified in this application relating to clinical aspects. The Committee adopted a request for supplementary information with a specific timetable.

## 9.1.7. Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0063, Orphan, ATMP

Kite Pharma EU B.V.

Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus
Committee for medicinal products for human use (CHMP)

Committee for medicinal products for human use (CHMP)

Scope: “Primary Analysis from study KTE-C19-107 (ZUMA-7); this is a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (DLBCL) in the 2nd line setting. In addition, the MAH took the opportunity to include the date of the latest renewal in section 9 and to submit a consolidated Environmental Risk Assessment (ERA) document.”

**Action:** For adoption

Request for Supplementary Information adopted on 06.10.2023.

The CHMP was updated on discussions at the CAT.

The Committee confirmed that all issues previously identified in this application had been addressed.

Based on the opinion adopted by the CAT, the CHMP adopted a positive opinion by consensus together with the CHMP assessment report and translation timetable.

### 9.1.8. Zynrelef - bupivacaine / meloxicam - EMEA/H/C/005205

Heron Therapeutics, Zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults.

**Rapporteur:** Alexandre Moreau, **Co-Rapporteur:** Elita Poplavska

Scope: Withdrawal of marketing authorisation

**Action:** For information

The CHMP noted the withdrawal of marketing authorisation.

### 9.1.9. Translarna - ataluren - EMEA/H/C/002720/R/0071, Orphan

PTC Therapeutics International Limited

Scope: Appointment of re-examination rapporteurs

**Action:** For adoption


The CHMP appointed a re-examination rapporteur and a re-examination Co-Rapporteur.

The CHMP noted the re-examination timetable.

### 9.1.10. Pazenir – paclitaxel – EMEA/H/C/004441

Ratiopharm GmbH

Rapporteur: Daniela Philadelphy

Scope: DHPC and communication plan

**Action:** For adoption

Follow-up discussions from the October CHMP plenary. The CHMP did not consider a DHPC
appropriate to communicate on shortages of medicinal products, but to communicate by other means, e.g. list the product in the shortage catalogue on the EMA website.

The Committee did not adopt the DHPC and communication plan for Pazenir.

At a future PROM, further discussion is expected on the communication of shortages and specifically on criteria to identify situations when a DHPC is considered appropriate for a shortage.

9.1.11. Blenrep - belantamab mafodotin - EMEA/H/C/004935/R/0017, Orphan

GlaxoSmithKline (Ireland) Limited
Scope: Re-examination, list of questions to SAG

Action: For adoption


The CHMP adopted the list of questions to the SAG.

10. Referral procedures


10.1.1. Ocaliva - obeticholic acid - EMEA/H/A-20/1531

Advanz Pharma Limited
Referral Rapporteur: Carolina Prieto Fernandez, Referral Co-Rapporteur: Paolo Gasparini

Scope: Revised timetable

Action: For adoption

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of Ocaliva (obeticholic acid). The review was prompted by final study results raising concerns of a potential lack of efficacy and worsened safety profile. These findings need to be reviewed in the context of all available data and their potential impact on the benefit-risk of Ocaliva assessed. In addition, the EC requests the Agency/CHMP to give its opinion, as soon as possible, as to whether temporary measures are necessary to ensure the safe and effective use of this medicinal product taking into account, amongst other elements, findings from the type II variation procedure EMEA/H/C/004093/II/0038.

The CHMP adopted a revised timetable.

Notification: 12 October 2023
Start of the procedure (CHMP): October 2023 CHMP
List of questions: 12 October 2023
Submission of responses: 01 December 2023
Re-start of the procedure: 26 December 2023
Rapporteur/co-rapporteur assessment report(s) circulated to CHMP: 05 January 2024
Comments: 11 January 2024
Updated Rapporteur/co-rapporteur ARs circulated to CHMP: 17 January 2024
CHMP list of outstanding issues or CHMP opinion: January 2024 CHMP

10.1.2. **Mysimba - naltrexone hydrochloride / bupropion hydrochloride - EMEA/H/C/003687/A20/0065**

Orexigen Therapeutics Ireland Limited
Referral Rapporteur: Thalia Marie Estrup Blicher, Referral Co-Rapporteur: Daniela Philadelphia
Scope: Letters from the MAH and response from EMA

**Action:** For information

The European Commission (EC) initiated a procedure under Article 20 of Regulation (EC) No 726/2004 and requested the Agency/CHMP to assess the benefit-risk balance of Mysimba (naltrexone/bupropion), taking into account any consequences from the failure to comply with the obligations laid down in the marketing authorisation.

This review of all available data on the potential long-term cardiovascular risk and its impact on the benefit-risk balance of Mysimba in its approved indication was considered needed in view of the remaining concern and lack of adequate study plan to address the uncertainty about this risk.

The CHMP noted the communication from the MAH and the response letter from EMA.

10.2. **Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004**

No items

10.3. **Procedure under Articles 5(2) and 10 of Regulation (EC) No 726/2004**

No items

10.4. **Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

No items
10.5. **Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

### 10.5.1. Havrix - EMEA/H/A-30/1527

GlaxoSmithKline Biologicals  
**Referral Rapporteur:** Maria Grazia Evandri, **Referral Co-Rapporteur:** Lyubina Racheva Todorova  
**Scope:** List of question  
**Action:** For adoption  
Harmonisation exercise for Havrix and associated names. Product Information harmonisation was triggered by the MAH.  
The CHMP adopted a list of questions with a specific timetable.  
**CHMP list of questions:** November 2023 CHMP  
**Submission of responses:** 04 January 2024  
**Re-start of the procedure:** 25 January 2024  
**Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP:** 01 February 2024  
**Comments:** 08 February 2024  
**Updated Rapporteur/co-rapporteur joint assessment report(s) circulated to CHMP:** 14 February 2024  
**CHMP list of outstanding issues or CHMP opinion:** February 2024 CHMP


### 10.6.1. Azithromycin containing medicinal products for systemic use – EMEA/H/A-31/1532

MAH various (NAPs only)  
**Referral Rapporteur:** Janet Koenig, **Referral Co-Rapporteur:** Maria Concepcion Prieto Yerro  
**Scope:** Start of procedure, appointment of Rapporteurs, timetable, list of questions  
**Action:** For adoption  
Need to re-evaluate the benefit-risk ratio of the approved indications considering the current scientific knowledge, the increasing resistance rate, the consumption data suggesting overuse and the different indications in the EU Member States. Furthermore, the appropriate dose and duration of administration for both oral and intravenous formulations need to be discussed as well as the adequacy of safety relevant information, information on pregnancy and breastfeeding and pharmacological properties.  
The German National Competent Authority triggered a referral under Article 31 of Directive 2001/83 based on interest of the Union, requesting an opinion to CHMP on the benefit-risk
of azithromycin-containing products and whether marketing authorisations of azithromycin-containing products for systemic use should be maintained, varied, suspended or revoked.

The CHMP appointed Janet Koenig as Referral Rapporteur and Maria Concepcion Prieto Yerro as Referral Co-Rapporteur.

The CHMP adopted a list of questions with a specific timetable.

Start of the procedure (CHMP): November 2023 CHMP
List of questions: 9 November 2023
Submission of responses: 4 January 2024
Re-start of the procedure: 25 January 2024

Rapporteur/co-rapporteur assessment reports circulated to CHMP: 26 February 2024
Comments: 7 March 2024
Updated Rapporteur/co-rapporteur assessment reports circulated to CHMP: 13 March 2024
CHMP list of outstanding issues / CHMP opinion: March 2024 CHMP

No items

No items

10.9. Disagreement between Member States on Type II variation–Arbitration procedure initiated by MAH under Article 6(13) of Commission Regulation (EC) No 1084/2003
No items

No items

10.11. Referral under Article 13 Disagreement between Member States on Type II variation–Arbitration procedure initiated by Member State under Article 13 (EC) of Commission Regulation No 1234/2008
No items
11. Pharmacovigilance issue

11.1. Early Notification System

November 2023 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

**Action:** For information

The CHMP noted the information.

12. Inspections

12.1. GMP inspections

Information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

No items

13.2. Innovation Task Force briefing meetings

No items

No items

13.4. **Nanomedicines activities**

No items

14. **Organisational, regulatory and methodological matters**

14.1. **Mandate and organisation of the CHMP**

14.1.1. **Vote by proxy**

Sol Ruiz gave a proxy to Maria Concepcion Prieto Yerro for the whole meeting.

14.1.2. **CHMP membership**

CHMP co-opted membership

The current expertise of Jan-Mueller-Berghaus is ‘Quality, safety and efficacy of biological medicinal products, including advanced therapies, and with specific emphasis on vaccines.’

The CHMP agreed that a co-opted member should be appointed in the following area of expertise: Quality, safety and efficacy of biological medicinal products, including advanced therapies, and with specific emphasis on vaccines and biosimilars. A call for nomination of a co-opted member was launched following the October 2023 plenary.

Nomination(s) received

**Action:** For election

The CHMP elected Jan-Mueller-Berghaus as co-opted member for another 3-year term.

14.1.3. **Guidance on SmPC section 5.1**

**Action:** For discussion

The CHMP discussed the next steps for the guidance on SmPC section 5.1.

EMA will draft the timelines for the next steps and inform the network accordingly.

14.2. **Coordination with EMA Scientific Committees**

14.2.1. **Pharmacovigilance Risk Assessment Committee (PRAC)**

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for November 2023
Action: For adoption
The CHMP adopted the EURD list.

14.2.2. Paediatric Committee (PDCO)

Agenda of the November 2023 PDCO plenary meeting
Action: For information
The CHMP noted the PDCO agenda.

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Biologics Working Party (BWP)

Chair: Sean Barry, Vice-chair: Francesca Luciani
Reports from BWP November 2023 meeting to CHMP for adoption:
- 14 reports on products in scientific advice and protocol assistance
- 14 reports on products in pre-authorisation procedures
- 1 report on products in post-authorisation procedures
- 6 reports on products in plasma master file
Action: For adoption
The CHMP adopted the BWP reports.

14.3.2. Scientific Advice Working Party (SAWP)

Chair: Paolo Foggi
Report from the SAWP meeting held on 23-26 October 2023. Table of conclusions
Action: For information
Scientific advice letters:
Information related to scientific advice letters cannot be released at present time as these contain commercially confidential information.
The CHMP noted the update.

14.4. Cooperation within the EU regulatory network

No items

14.5. Cooperation with International Regulators

No items
14.6. **Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee**

No items

14.7. **CHMP work plan**

No items

14.8. **Planning and reporting**

No items

14.9. **Others**

14.9.1. **CHMP Learnings**

CHMP: Outi Mäki-Ikola

Collection, discussion and recording of CHMP learnings.

*Action:* For information

The CHMP noted the CHMP learnings.

15. **Any other business**

15.1. **AOB topic**

No items
List of participants

List of participants including any restrictions with respect to involvement of members/alternates/experts following evaluation of declared interests for the 06-09 November 2023 CHMP meeting, which was held in-person.

An asterisk (*) after the role, in the second column, signals that the member/alternate attended remotely. Additional experts participated in (part of) the meeting, either in person or remotely.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harald Enzmann</td>
<td>Chair</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Daniela Philadelphia</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christian Gartner</td>
<td>Alternate</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Christophe Focke</td>
<td>Member</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Karin Janssen van Doorn</td>
<td>Alternate</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lyubina Racheva Todorova</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Gergana Lazarova</td>
<td>Alternate</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Margareta Bego</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Selma Arapovic Dzakula</td>
<td>Alternate</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Helena Panayiotopoulou</td>
<td>Member</td>
<td>Cyprus</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tomas Radimersky</td>
<td>Member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Petr Vrba</td>
<td>Alternate*</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Thalia Marie Estrup Blicher</td>
<td>Member</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Aaron Sosa Mejia</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Alar Irs</td>
<td>Member</td>
<td>Estonia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Edward Laane</td>
<td>Alternate</td>
<td>Estonia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Outi Mäki-Ikola</td>
<td>Member</td>
<td>Finland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Johanna Lähteenvuo</td>
<td>Alternate</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alexandre Moreau</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Michel Race</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Martina Weise</td>
<td>Member</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Janet Koenig</td>
<td>Alternate</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Konstantina Alexopoulou</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anastasia Mountaki</td>
<td>Alternate</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Robert Porszasz</td>
<td>Member</td>
<td>Hungary</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Beata Maria Jakline Ullrich</td>
<td>Alternate</td>
<td>Hungary</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hrefna Gudmundsdottir</td>
<td>Member</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hjalti Kristinsson</td>
<td>Alternate</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jayne Crowe</td>
<td>Member</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------------</td>
<td>----------------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Finbarr Leacy</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Grazia Evandri</td>
<td>Alternate</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Elita Poplavska</td>
<td>Member</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Vilma Petrikaite</td>
<td>Member</td>
<td>Lithuania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Larisa Gorobets</td>
<td>Alternate*</td>
<td>Lithuania</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Martine Trauffer</td>
<td>Member</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alexandra Branchu</td>
<td>Alternate</td>
<td>Luxembourg</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>John Joseph Borg</td>
<td>Member</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Peter Mol</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Patrick Vrijlandt</td>
<td>Alternate</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ingrid Wang</td>
<td>Member</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Eva Skovlund</td>
<td>Alternate</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ewa Balkowiec Iskra</td>
<td>Member</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bruno Sepodes</td>
<td>Member (Vice-Chair)</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Fatima Ventura</td>
<td>Alternate</td>
<td>Portugal</td>
<td>No participation in final deliberations and voting on:</td>
<td>COVID-19 vaccines</td>
</tr>
<tr>
<td>Dana Gabriela Marin</td>
<td>Alternate</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Frantisek Drafi</td>
<td>Member</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Dorota Distlerova</td>
<td>Alternate*</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Andreja Kranjc</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Concepcion Prieto Yerro</td>
<td>Member</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carolina Prieto Fernandez</td>
<td>Alternate</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristina Dunder</td>
<td>Member</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Filip Josephson</td>
<td>Alternate</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bruno Delafont</td>
<td>Co-opted member</td>
<td>France</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Carla Torre</td>
<td>Co-opted member</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Co-opted member</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Blanka Hirschlerova</td>
<td>Co-opted member</td>
<td>Czechia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Co-opted member*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Danica Juricic Nahal</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lidija Prka</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ivona Jukić</td>
<td>Expert</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Magdalena Kremer</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Peter Mayer</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jana Klimasová</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Anna Kubandová</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ivana Rusňáková</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jana Schweigertová</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Peter Šišovský</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Eva Malikova</td>
<td>Expert</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Charlotte Anderberg</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-------</td>
<td>----------------------</td>
<td>--------------------------------------------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>Jenny-Maria Jönsson</td>
<td>Expert</td>
<td>Sweden</td>
<td>No participation in final deliberations and voting on: Tecentriq - atezolizumab - EMEA/H/C/004143 /X/0076</td>
<td></td>
</tr>
<tr>
<td>Matti Karvanen</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Karin Fjordén</td>
<td>Expert</td>
<td>Sweden</td>
<td>No participation in final deliberations and voting on: Keytruda - pembrolizumab - EMEA/H/C/003820 /II/0138</td>
<td></td>
</tr>
<tr>
<td>Daiana Vasilcanu</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Helena Faust</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Vincent Gazin</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Glenn Lastennet</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Roxane Fornacciari</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nicolas Beix</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Isabelle Puff</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Brenda Holingue</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lama Caizergues Sargi</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marika Doucet</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ieva Rutkovska</td>
<td>Expert</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Diāna Inga Paegle</td>
<td>Expert</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kairi Rooma</td>
<td>Expert</td>
<td>Estonia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rune Kjeken</td>
<td>Expert</td>
<td>Norway</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kristine Moltu</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Fabrice Eroukhmanoff</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nina Pettersen Hessvik</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Lena Eroukhmanoff</td>
<td>Expert</td>
<td>Norway</td>
<td>No participation in discussion, final deliberations and voting on: Rystiggo - rozanolixizumab - Orphan - EMEA/H/C/005824</td>
<td></td>
</tr>
<tr>
<td>Paolo Foggi</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Elisabeth Wischnitzki</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anna Vikerfors</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Flora Musuamba</td>
<td>Expert</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Carin Bergquist</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Karri Penttilä</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Paile-Hyvärinen</td>
<td>Expert</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kinga Nowicka-Matus</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ebru Karakoc Madsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Boje Kvorning Pires Ehmsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mette Linnert Jensen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Torsten Holm Nielsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristina Bech Jensen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Line Praest Lauridsen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Deirdre Mannion</td>
<td>Expert</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kristin Skougaard</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Anne-Marie Dalseg</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Camilla Göktürk</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>--------</td>
<td>----------------------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Céline Jumeau</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mona Kassem-Youssef</td>
<td>Expert</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marta Lafuente Gonzalez</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Macarena Gajardo Alvarez</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Beatriz Gutiérrez Eugenio</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Agustín Portela</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alicia Pérez González</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ana Sagredo</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Daniel Fernández Soto</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Rosa Virto</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Carmen de la Morena Criado</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ana Moreno Oliver</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Luisa Valer Lopez-Fando</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Andrea García Caballero</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Eva Maria Nadal Elduayen</td>
<td>Expert</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marte Fergestad</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maja Sommerfelt Grønvid</td>
<td>Expert</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Viktor András Billes</td>
<td>Expert</td>
<td>Hungary</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Olga Kholmanskikh</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alexandru-Mihail Simion</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Stefan Bonné</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nicolas Nyssen</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Valérie Lescrainier</td>
<td>Expert</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Harald Bernsteininer</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Walter Johannes Beiersdorf</td>
<td>Expert</td>
<td>Austria</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Matthias Braun</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hannah Münch</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tobias Glüxam</td>
<td>Expert</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Edo Richard</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No restrictions against giving the SAG report on Qalsody</td>
<td></td>
</tr>
<tr>
<td>Adriana Ammassari</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Luca Santi</td>
<td>Expert</td>
<td>Italy</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Martina Perini</td>
<td>Expert</td>
<td>Italy</td>
<td>No participation in discussion, final deliberations and voting on:</td>
<td></td>
</tr>
<tr>
<td>Cristina Migali</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td>Tepadina - thiotepa - EMEA/H/C/001046/X/0049</td>
</tr>
<tr>
<td>Serena Zamponi</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Gabriella Passacquale</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Milica Mitrevski</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Cinzia Ciceroni</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Valentina Conti</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angela Garau</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Antonella Isgrò</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angelo Molinaro</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Michela Piezzo</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Larissa Higgins</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>------------------------------</td>
<td>--------</td>
<td>----------------------------</td>
<td>-----------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Brian Aylward</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sinead Harrington</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Benita Cullen</td>
<td>Expert</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Cathrine Wisbech</td>
<td>Expert</td>
<td>Norway</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Katja Findeisen</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Juliane Rau</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Attila Sebe</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Benjamin Hofner</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Michal Zwiewka</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Irene Nowotny</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Annette Lommel</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Poleta Luga</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Niklas Walther</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Hilke Zander</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Julia Katharina Maier</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Susanne Müller-Egert</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jörg Engelbergs</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Matea Cartolano</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Yasmin Molter</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Robert Pollmann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mark van Bussel</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hinke Johanna van der Woude</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Angela de Kleynen</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Friederike Marei Feldmann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Febrin Hennemann</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Georgios Aislaitner</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Andreas Brandt</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Marion Haberkamp</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sylvia Kühn</td>
<td>Expert</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Miriam Fürst-Wilmes</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Danila Renzo</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Valeria Zuccaro</td>
<td>Expert</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Loes den Otter</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Thurid Buch</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Emline Leon</td>
<td>Expert</td>
<td>France</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Sigurros Sigmarsdottir</td>
<td>Expert</td>
<td>Iceland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Kristian Wennmalm</td>
<td>Expert</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Norbert Benda</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-------------------------------</td>
<td>----------</td>
<td>----------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Tarec Christoffer El-Galaly</td>
<td>Expert</td>
<td>Denmark</td>
<td>No restrictions against giving the SAG report for Krazati</td>
<td></td>
</tr>
<tr>
<td>Sine Buhl Næss-Schmidt</td>
<td>Expert</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Emilie Birch Kristensen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Maria Victoria Tudanca Pacios</td>
<td>Expert</td>
<td>Spain</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Thadeus Bao Quan Nguyen</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mette Steen Tranholm</td>
<td>Expert</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Susan Uiterwaal</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johanna de Groot</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Martijn van Gils</td>
<td>Expert</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sabine Mayrhofer</td>
<td>Expert</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Gunnar Thor Gunnarsson</td>
<td>Expert</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kira Blankenbach</td>
<td>Expert</td>
<td>Swissmedic</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Regula Johner</td>
<td>Expert</td>
<td>Swissmedic</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Thomas Schochat</td>
<td>Expert</td>
<td>Swissmedic</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>

A representative from the European Commission attended the meeting.

Meeting run with the help of EMA staff.

Experts were evaluated against the agenda topics or activities they participated in.
Experts from international organisations or regulatory authorities in third countries cannot participate in the adoption of any procedural decision, scientific opinion or recommendation by the Committee at any step of the procedure.
Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

**Oral explanations (section 2)**

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

**Initial applications (section 3)**

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of an application for a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (**Day 180 List of outstanding issues**) and 3.3 (**Day 120 list of questions**).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, **update on ongoing new applications for centralised procedures**.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, **products in the decision making phase**.
Extension of marketing authorisations according to Annex I of Reg. 1234/2008 (section 4)

Extensions of marketing authorisations are applications for the change or addition of new strengths, formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

Type II variations - Extension of indication procedures (section 5)

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

Ancillary medicinal substances in medical devices (section 6)

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004 (section 3.5)

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

Re-examination procedures (section 5.3)

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

Withdrawal of application (section 3.7)

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use) (section 7)

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

Pre-submission issues (section 8)

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

Post-authorisation issues (section 9)

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.
Referral procedures (section 10)

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

Pharmacovigilance issues (section 11)

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

Inspections Issues (section 12)

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

Innovation task force (section 13)

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

Scientific advice working party (SAWP) (section 14.3.1)

This section refers to the monthly report from the CHMP’s Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

Satellite groups / other committees (section 14.2)

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

Invented name issues (section 14.3)

This section lists issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group’s main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/
Annex to 06-09 November 2023 CHMP Minutes
Pre-submission and post-authorisations issues

A. PRE-SUBMISSION ISSUES ................................................................. 3
A.1. ELIGIBILITY REQUESTS................................................................. 3
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications ................. 3
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION .............................. 3

B. POST-AUTHORISATION PROCEDURES OUTCOMES ...................... 3
B.1. Annual re-assessment outcomes ...................................................... 3
B.1.1. Annual reassessment for products authorised under exceptional circumstances .... 3
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES............. 3
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal ................. 3
B.2.2. Renewals of Marketing Authorisations for unlimited validity .................... 3
B.2.3. Renewals of Conditional Marketing Authorisations ................................ 5
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES .......... 5
B.4. EPARs / WPARs ............................................................... 7
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES ......... 9
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects .................. 9
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .......... 14
B.5.3. CHMP-PRAC assessed procedures .............................................. 24
B.5.4. PRAC assessed procedures ....................................................... 29
B.5.5. CHMP-CAT assessed procedures ................................................. 34
B.5.6. CHMP-PRAC-CAT assessed procedures ........................................ 36
B.5.7. PRAC assessed ATMP procedures ............................................... 36
B.5.8. Unclassified procedures and worksharing procedures of type I variations .... 36
B.5.9. Information on withdrawn type II variation / WS procedure .................. 38
B.5.10. Information on type II variation / WS procedure with revised timetable .... 39
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION ........ 39
B.6.1. Start of procedure for New Applications: timetables for information ........... 39
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information ....................................................... 40
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information ................................................................. 42
B.6.4. Annual Re-assessments: timetables for adoption .................................................. 43
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed ................................................................. 44
B.6.6. VARIATIONS – START OF THE PROCEDURE ................................................................. 45
B.6.7. Type II Variations scope of the Variations: Extension of indication ....................... 45
B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects ........................................ 50
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects .................... 52
B.6.10. CHMP-PRAC assessed procedures .................................................................. 56
B.6.11. PRAC assessed procedures ............................................................................. 57
B.6.12. CHMP-CAT assessed procedures .................................................................. 57
B.6.13. CHMP-PRAC-CAT assessed procedures ............................................................ 58
B.6.14. PRAC assessed ATMP procedures ................................................................. 58
B.6.15. Unclassified procedures and worksharing procedures of type I variations .......... 58
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY ..................................... 59
B.7.1. Yearly Line listing for Type I and II variations .................................................... 59
B.7.2. Monthly Line listing for Type I variations ........................................................... 59
B.7.3. Opinion on Marketing Authorisation transfer (MMD only) ................................. 59
B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only) ........................................................................................................... 59
B.7.6. Notifications of Type I Variations (MMD only) .................................................... 59
C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled) ................................................................. 59
D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed) ................................................................................................................. 59
E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES ..................................... 59
E.1. PMF Certification Dossiers .................................................................................. 60
E.1.1. Annual Update ............................................................................................... 60
E.1.2. Variations ..................................................................................................... 60
E.1.3. Initial PMF Certification ................................................................................... 60
E.2. Time Tables – starting & ongoing procedures: For information .............................. 60
F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver .... 60
G. ANNEX G ......................................................................................................... 60
G.1. Final Scientific Advice (Reports and Scientific Advice letters): .............................. 60
G.2. PRIME ............................................................................................................. 60
H. ANNEX H - Product Shared Mailboxes – e-mail address ........................................ 60
A. PRE-SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for November 2023: For adoption

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for November 2023: For adoption

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

<table>
<thead>
<tr>
<th>Product</th>
<th>Rapporteur/Co-Rapporteur</th>
<th>CHMP Opinion</th>
<th>Notes</th>
</tr>
</thead>
</table>

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

<table>
<thead>
<tr>
<th>Product</th>
<th>Rapporteur/Co-Rapporteur</th>
<th>CHMP Opinion</th>
<th>Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dectova - zanamivir - EMEA/H/C/004102/R/0017</td>
<td>GlaxoSmithKline Trading Services Limited, Rapporteur: Ingrid Wang, Co-Rapporteur: Bruno Sepodes, PRAC Rapporteur: Ulla Wändel Liminga</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can</td>
</tr>
<tr>
<td>Product</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------</td>
<td>---------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mulpleo - lusutrombopag</strong> - EMEA/H/C/004720/R/0018</td>
<td>be granted with unlimited validity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shionogi B.V., Rapporteur: Daniela Philadelphy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Mari Thorn Request for Supplementary Information adopted on 14.09.2023.</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pazeni - paclitaxel</strong> - EMEA/H/C/004441/R/0015</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ratiopharm GmbH, Generic, Generic of Abraxane, Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Menno van der Elst</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Palynziq - Pegvaliase</strong> - EMEA/H/C/004744/R/0038, Orphan</td>
<td>Request for supplementary information adopted with a specific timetable.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Skyrizi - risankizumab</strong> - EMEA/H/C/004759/R/0039</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Trecondi - treosulfan</strong> - EMEA/H/C/004751/R/0019, Orphan</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable. Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>medac Gesellschaft für klinische Spezialprparate mbH, Rapporteur: Fátima Ventura, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Julia Pallos</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
B.2.3. Renewals of Conditional Marketing Authorisations

B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES

Signal detection
PRAC recommendations on signals adopted at the PRAC meeting held on 23-26 October 2023

<table>
<thead>
<tr>
<th>Signal of acquired phimosis and phimosis</th>
<th>Adopted</th>
</tr>
</thead>
<tbody>
<tr>
<td>Edistride, Forxiga, Ebymect, Xigduo, Qtern (CAP &amp; NAP) – Dapagliflozin</td>
<td></td>
</tr>
<tr>
<td>Rapporteur: multiple, Co-Rapporteur: multiple, PRAC Rapporteur: Mari Thorn</td>
<td></td>
</tr>
<tr>
<td>PRAC recommendation on a variation</td>
<td></td>
</tr>
<tr>
<td><strong>Action:</strong> For adoption</td>
<td></td>
</tr>
</tbody>
</table>

PSUR procedures for which PRAC adopted a recommendation for variation of the terms of the MA at its November 2023 meeting:

**EMEA/H/C/PSUSA/00002491/202304** (pramipexole)
CAPS: **Mirapexin** (EMEA/H/C/000134) (pramipexole), Boehringer Ingelheim International GmbH, Rapporteur: Thalia Marie Estrup Blicher
NAPS: **NAPs** – EU
PRAC Rapporteur: Karin Erneholm, “06/04/2022 To: 06/04/2023”
The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 and Article 107g(3) of Directive 2001/83/EC the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the medicinal products containing the above referred active substance(s), concerning the following change(s):
Update of sections 4.2, 4.4 and 4.8 of the SmPC to highlight that the lowest effective dose should be used, amend the warning/precaution regarding restless legs augmentation syndrome and to add the adverse reaction restless legs augmentation syndrome with a frequency ‘very common’. The package leaflet is updated accordingly.

**EMEA/H/C/PSUSA/00010499/202303** (eftrenonacog alfa)
CAPS: **Alprolix** (EMEA/H/C/004142) (eftrenonacog alfa), Swedish Orphan Biovitrum AB (publ), Rapporteur: Daniela Philadelphy, PRAC Rapporteur: Gabriele Maurer, “20/03/2020 To: 19/03/2023”
The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends, by consensus, the variation to the terms of the marketing authorisation for the above-mentioned medicinal product, concerning the following change(s):
Update of section 4.8 of the SmPC to include “Anaphylactic Shock” as an Adverse Drug Reaction with frequency unknown. The package leaflet is updated accordingly.
The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.4 of the SmPC to amend a warning/precaution regarding the risk of autoimmune reactions. The package leaflet is updated accordingly.

Update of sections 4.4 and 4.8 of the SmPC to amend a warning/precaution regarding other immune-related adverse reactions and add the adverse reaction sarcoidosis with a frequency uncommon. The package leaflet is updated accordingly.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction proteinuria with a frequency common. The package leaflet is updated accordingly.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to amend the PML frequency from “unknown” to “rare”. The package leaflet is updated accordingly.

Update of section 4.4 of the SmPC to amend a warning regarding reduction in heart rate and atrioventricular conduction.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to amend the PML frequency from “unknown” to “rare”. The package leaflet is updated accordingly.

Update of section 4.4 of the SmPC to amend a warning regarding reduction in heart rate and atrioventricular conduction.
CAPS: **Jyseleca** (EMEA/H/C/005113) (Filgotinib), Galapagos N.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Nikica Mirošević Skvrce, "24/09/2022 To 23/03/2023"  
the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):  
Update of sections 4.7 and 4.8 of the SmPC to add the adverse reaction vertigo with a frequency of uncommon. The package leaflet should be updated accordingly.

EMEA/H/C/PSUSA/00010921/202303  
(cenobamate)  
CAPS: **Ontozry** (EMEA/H/C/005377) (Cenobamate), Angelini S.p.A., Rapporteur: Bruno Sepodes, PRAC Rapporteur: Jo Robays, “19/05/2022 To: 26/03/2023”  
The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):  
Update of sections 4.4 and 4.8 of the SmPC to amend /add information relating to suicidality following the use of cenobamate. The package leaflet is updated accordingly.

EMEA/H/C/PSUSA/00011003/202303  
(olipudase alfa)  
CAPS: **Xenpozyme** (EMEA/H/C/004850) (Olipudase alfa), Sanofi B.V., Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Martin Huber, “28/09/2022 To: 28/03/2023”  
The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):  
Update of sections 4.2, 4.4 and 4.9 of the SmPC to amend the wording about the dose escalation scheme and to reflect the cases of overdose. The package leaflet is updated accordingly.

**B.4. EPARs / WPARs**

**Agamree - vamorolone -**  
EMEA/H/C/005679, Orphan  
Santhera Pharmaceuticals (Deutschland) GmbH, treatment of Duchenne muscular dystrophy (DMD), New active substance (Article 8(3) of Directive No 2001/83/EC)  
For information only. Comments can be sent to the PL in case necessary.

**Elrexfio - elranatamab -**  
EMEA/H/C/005908  
For information only. Comments can be sent to
<table>
<thead>
<tr>
<th><strong>EMA/CHMP/500954/2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pfizer Europe MA EEIG</strong>, treatment of adult patients with relapsed or refractory multiple myeloma, New active substance (Article 8(3) of Directive No 2001/83/EC)</td>
</tr>
</tbody>
</table>
| **Elucirem - gadopiclenol -**  
**EMEA/H/C/005626**  
Guerbet, for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate),, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| **Loargys - pegzilarginase -**  
**EMEA/H/C/005484, Orphan**  
Immedica Pharma AB, treatment of hyperargininemia, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| **Rezzayo - rezafungin -**  
**EMEA/H/C/005900, Orphan**  
Mundipharma GmbH, treatment of invasive candidiasis, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| **Sugammadex Lorien (WD) - sugammadex -**  
**EMEA/H/C/006115**  
LABORATORIOS LORIEN, S.L, reversal of neuromuscular blockade induced by rocuronium or vecuronium, Generic, Generic of Bridion, Generic application (Article 10(1) of Directive No 2001/83/EC) | WPAR  
For information only. Comments can be sent to the PL in case necessary. |
| **Veozza - fezolinetant -**  
**EMEA/H/C/005851**  
Astellas Pharma Europe B.V., treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
| **Vueway - gadopiclenol -**  
**EMEA/H/C/006172**  
Bracco Imaging S.p.A., for diagnostic: contrast-enhanced magnetic resonance imaging (MRI) to improve detection, visualisation and assist in characterisation of lesions in the central nervous system and in other body regions (including breast, liver and prostate),, Duplicate, Duplicate of Elucirem, New active substance (Article 8(3) of Directive No 2001/83/EC) | For information only. Comments can be sent to the PL in case necessary. |
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects

<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA Reference</th>
<th>Reporter</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Product Name</td>
<td>EMEA Reference Number</td>
<td>Rapporteur</td>
<td>Opinion Date</td>
</tr>
<tr>
<td>--------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>--------------------------------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flucelvax Tetra - Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) -</td>
<td>EMEA/H/C/004814/II/0039</td>
<td>Seqirus Netherlands B.V., Rapporteur: Sol Ruiz</td>
<td>09.11.2023</td>
</tr>
<tr>
<td>Flucelvax Tetra - Influenza vaccine (surface antigen, inactivated, prepared in cell cultures) -</td>
<td>EMEA/H/C/004814/II/0041</td>
<td>Seqirus Netherlands B.V., Rapporteur: Sol Ruiz</td>
<td>09.11.2023</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemlibra - Emicizumab</td>
<td>EMEA/H/C/004406/II/0037</td>
<td>Roche Registration GmbH, Rapporteur: Alexandre Moreau</td>
<td>09.11.2023</td>
</tr>
<tr>
<td>Product Name</td>
<td>EMEA/H/C/XXXXX/II/00XX</td>
<td>Company</td>
<td>Rapporteur</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------</td>
<td>---------</td>
<td>------------</td>
</tr>
<tr>
<td>Product Name</td>
<td>Marketing Authorization Number</td>
<td>Rapporteur</td>
<td>Request for Supplementary Information Adopted</td>
</tr>
<tr>
<td>------------------------------------</td>
<td>--------------------------------</td>
<td>------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Product</td>
<td>EMEA/CHMP/500954/2023</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------</td>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| **Toujeo** - Insulin glargine -  
EMEA/H/C/000309/II/0127/G  
Sanofi-Aventis Deutschland GmbH, Duplicate,  
Duplicate of Lantus, Rapporteur: Patrick Vrijlandt  
Request for Supplementary Information adopted on 09.11.2023. | Request for supplementary information adopted with a specific timetable. |
| **Vaxelis** - Diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) -  
EMEA/H/C/003982/II/0132  
MCM Vaccine B.V., Rapporteur: Christophe Focke  
| **Xgeva** - denosumab -  
EMEA/H/C/002173/II/0082/G  
Amgen Europe B.V., Rapporteur: Kristina Dunder  
Request for Supplementary Information adopted on 19.10.2023. | Request for supplementary information adopted with a specific timetable. |
| **Zaltrap** - aflibercept -  
EMEA/H/C/002532/II/0069/G  
Sanofi Winthrop Industrie, Rapporteur: Filip Josephson  
Request for Supplementary Information adopted on 19.10.2023. | Request for supplementary information adopted with a specific timetable. |
| **WS2522/G**  
Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-  
EMEA/H/W/005362/WS2522/0007/G  
Qdenga-  
EMEA/H/C/005155/WS2522/0008/G  
Takeda GmbH, Lead Rapporteur: Sol Ruiz  
| **WS2547**  
Blitzima-  
EMEA/H/C/004723/WS2547/0068  
Truxima-  
EMEA/H/C/004112/WS2547/0071  
Celltrion Healthcare Hungary Kft., Lead Rapporteur: Sol Ruiz  
### B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

<table>
<thead>
<tr>
<th>Product</th>
<th>Description</th>
<th>Status</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AREXVY</strong> - Respiratory syncytial virus, glycoprotein F, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E - EMEA/H/C/006054/II/0002/G</td>
<td>GlaxoSmithkline Biologicals S.A., Rapporteur: Patrick Vrijlandt, &quot;Update of section 4.5 of the SmPC in order to update information on the co-administration with inactivated seasonal quadrivalent influenza vaccines: with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV) based on final results from studies RSV OA=ADJ-008 and RSV OA=ADJ-017. These are Phase III studies intended to evaluate the immune response, safety and reactogenicity of Arexvy when co-administered with a high dose unadjuvanted influenza vaccine (FLU HD) and a standard dose adjuvanted influenza vaccine (FLU aQIV), respectively.” Request for Supplementary Information adopted on 09.11.2023.</td>
<td>Request for supplementary information adopted with a specific timetable. See 9.1</td>
</tr>
<tr>
<td>Product Name</td>
<td>Market Authorization Number</td>
<td>Rapporteur</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------</td>
<td>------------</td>
</tr>
<tr>
<td><strong>Dynastat - Parecoxib</strong></td>
<td>EMEA/H/C/000381/II/0088</td>
<td>Pfizer Europe MA EEIG, Finbarr Leacy</td>
</tr>
<tr>
<td><strong>Fabrazyme - agalsidase beta</strong></td>
<td>EMEA/H/C/000370/II/0129</td>
<td>Sanofi B.V., Patrick Vrijlandt</td>
</tr>
<tr>
<td><strong>INMIVREE - setmelanotide -</strong></td>
<td><strong>Positive Opinion adopted by consensus on 26.10.2023.</strong></td>
<td></td>
</tr>
<tr>
<td>-------------------------------</td>
<td>-----------------------------------------------------</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Keytruda - Pembrolizumab -</strong></th>
<th><strong>Positive Opinion adopted by consensus on 09.11.2023.</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMEA/H/C/003820/II/0139</strong></td>
<td>Merck Sharp &amp; Dohme B.V., Rapporteur: Paolo Gasparini, &quot;Update of section 5.1 of the SmPC in order to update clinical information, based on results from study KEYNOTE-716 listed as a PAES in the Annex II. This is a randomized, double-blind phase 3 study of adjuvant therapy with pembrolizumab versus placebo in resected high-risk stage II melanoma. The Annex II is updated accordingly.” Opinion adopted on 09.11.2023. Request for Supplementary Information adopted on 31.08.2023.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Lonquex - lipegfilgrastim -</strong></th>
<th><strong>Positive Opinion adopted by consensus on 26.10.2023.</strong></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th><strong>Mounjaro - Tirzepatide -</strong></th>
<th><strong>Positive Opinion adopted by consensus on 09.11.2023.</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EMEA/H/C/005620/II/0010</strong></td>
<td>Eli Lilly Nederland B.V., Rapporteur: Martina Weise, &quot;Update of section 4.8 of the SmPC in order to add ‘anaphylactic reaction’ and ‘angioedema’ to the list of adverse drug reactions (ADRs) with frequency rare, based on reviews of post-marketing safety data. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to</td>
</tr>
</tbody>
</table>

introduce minor changes to the PI.”
Request for Supplementary Information adopted on 07.09.2023.

NUVAXOVID - Covid-19 vaccine (recombinant, adjuvanted) - EMEA/H/C/005808/II/0058/G
Novavax CZ, a.s., Rapporteur: Patrick Vrijlandt
See 9.1

Opzelura - ruxolitinib -
EMEA/H/C/005843/II/0003
Incyte Biosciences Distribution B.V.,
Rapporteur: Peter Mol, "Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to update posology, safety and efficacy information based on final results from study INCB 18424-308; this is a Phase III, double-blind, vehicle-controlled, randomized withdrawal and treatment-extension study to assess the long-term efficacy and safety of ruxolitinib cream in participants with vitiligo (TRuE-V LTE). The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC.”
Request for Supplementary Information adopted on 31.08.2023.

Paxlovid - Nirmatrelvir / Ritonavir -
EMEA/H/C/005973/II/0049/G
Pfizer Europe MA EEIG, Rapporteur: Jean-Michel Race, "Grouped application comprising two type II variations (C.I.4) as follows:
- Update of sections 4.4 and 4.8 of the SmPC in order to clarify that toxic epidermal necrolysis has been reported with Paxlovid and to add toxic epidermal necrolysis to the list of adverse drug reactions (ADRs) with frequency Rare based on the cumulative review of MAH safety database and literature.
- Update of sections 4.4 and 4.8 of the SmPC in order to clarify that Stevens-Johnson syndrome has been reported with Paxlovid and to add Stevens-Johnson syndrome to the list of adverse drug reactions (ADRs) with frequency Rare, based on the cumulative review of MAH safety database and literature.
The Package Leaflet is updated accordingly.”
Request for supplementary information adopted with a specific timetable.
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Phesgo - Pertuzumab / Trastuzumab - EMEA/H/C/005386/II/0021</strong></td>
<td>Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, “Submission of the final report from study MO40628 (PHRanceSCa), a Phase II, randomized, multicenter, open-label, cross-over study to evaluate patient reported preference for Phesgo compared with intravenous pertuzumab and trastuzumab in patients with HER2-positive EBC.” Opinion adopted on 09.11.2023.</td>
</tr>
<tr>
<td><strong>RAYVOW - Lasmiditan - EMEA/H/C/005332/II/0004</strong></td>
<td>Eli Lilly Nederland B.V., Rapporteur: Janet Koenig, “Update of sections 4.5 and 5.2 of the SmPC in order to add drug-drug interaction information with dabigatran and rosuvastatin based on the results from study LAIO, An Open-Label, 2-Part Study to Investigate the Effect of Lasmiditan on the Pharmacokinetics of Dabigatran and Rosuvastatin in Healthy Volunteers. The aim of study LAIO was to investigate the effect of lasmiditan on the pharmacokinetic profiles of dabigatran (a P-glycoprotein substrate) and rosuvastatin (breast cancer resistance protein substrate) in healthy volunteers. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.” Request for Supplementary Information adopted on 09.11.2023.</td>
</tr>
<tr>
<td><strong>Remsima - Infliximab - EMEA/H/C/002576/II/0133/G</strong></td>
<td>Celltrion Healthcare Hungary Kft., Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kimmo Jaakkola, ”Grouped application comprising three type II variations (C.I.4) as follows: - Update of sections 4.2, 4.8 and 5.1 of the SmPC in order to add 3-IV induction dosing regimen and dose escalation of subcutaneous maintenance dose from CT-P13 SC 120 mg Q2W to 240 mg Q2W for patients with loss of response and update efficacy and safety information based on week 54 data from studies CT-P13 3.7 (ulcerative colitis) and CT-P13 3.8 (crohn’s disease), listed as a category 3 study in See 9.1”</td>
</tr>
</tbody>
</table>

Request for supplementary information adopted with a specific timetable.
the RMP; study CT-P13 3.7 is a Randomized, Placebo Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Ulcerative Colitis and study CT-P13 3.8 is a Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of the Subcutaneous Injection of CT-P13 (CT-P13 SC) as Maintenance Therapy in Patients with Moderately to Severely Active Crohn’s Disease.

- Update of sections 4.2 and 5.2 of the SmPC in order to add subcutaneous induction posology and pharmacokinetic information based on Population PK and PK-PD Modelling and Simulation.
- Update of section 4.2 of the SmPC in order to switch from high-dose IV maintenance (> 5 mg/kg) to subcutaneous maintenance dose of 120 mg Q2W based on data from REMSWITCH study (Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study).

The RMP version 16.1 has also been submitted. The Package Leaflet and Labelling are updated accordingly. In addition, the MAH took the opportunity to introduce minor updates to the PI.”

Request for Supplementary Information adopted on 09.11.2023.

**RINVOQ - upadacitinib - EMEA/H/C/004760/II/0042**

AbbVie Deutschland GmbH & Co. KG, Rapporteur: Kristina Dunder, “Submission of the final report from study M13-545 listed as a category 3 study in the RMP (MEA/10). This is a Phase 3, Randomized, Double-Blind Study Comparing Upadacitinib (ABT-494) Once Daily Monotherapy to Methotrexate (MTX) Monotherapy in MTX-Naïve Subjects with Moderately to Severely Active Rheumatoid Arthritis.”


**Shingrix - herpes zoster vaccine (recombinant, adjuvanted) - EMEA/H/C/004336/II/0065**

GlaxoSmithkline Biologicals SA, Rapporteur:

Christophe Focke, "Update of section 4.5 of the SmPC in order to add drug-drug interaction information with COVID-19 mRNA-1273 booster vaccine, based on final results from study ZOSTER-091; this is a phase 3, randomized, open-label, controlled, multi-center clinical study to evaluate the immune response and safety of both herpes zoster subunit vaccine (HZ/su or Shingrix) in healthy adults aged 50 years and older, and the quadrivalent seasonal influenza vaccine (Flu D-QIV or Fluarix Quadrivalent) in healthy adults aged 18 years and older, when administered sequentially or co-administered with mRNA-1273 booster vaccination. The Package Leaflet is updated accordingly.”

**Spravato - esketamine -**  
**EMEA/H/C/004535/II/0018**  
Janssen-Cilag International N.V., Rapporteur: Martina Weise, “Update of section 5.1 of the SmPC in order to update efficacy and safety information based on the final results from study 54135419TRD3013 (ESCAPE). This is A Randomized, Open-label, Rater-Blinded, Active-Controlled, International, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Flexibly Dosed Esketamine Nasal Spray Compared With Quetiapine Extended-Release in Adult and Elderly Participants With Treatment-Resistant Major Depressive Disorder Who are Continuing a Selective Serotonin Reuptake Inhibitor/ Serotonin-Norepinephrine Reuptake Inhibitor.
In addition, the MAH took the opportunity to introduce minor editorial changes, to update Annex IV and to update the list of local representatives in the Package Leaflet.”

**Toviaz - fesoterodine -**  
**EMEA/H/C/000723/II/0068**  
Pfizer Europe MA EEIG, Rapporteur: Maria Concepcion Prieto Yerro, "Update of sections 4.4 of the SmPC to amend an existing warning on angioedema and 4.8 of the SmPC in order to
add hypoaesthesia oral to the list of adverse drug reactions (ADRs) with a frequency rare based on a cumulative review of safety database cases and literature. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the PI in line with the QRD template v10.3.” Opinion adopted on 19.10.2023.

**Veklury - Remdesivir -**
**EMEA/H/C/005622/II/0052**
Gilead Sciences Ireland UC, Rapporteur: Janet Koenig, "Update of section 5.1 of the SmPC with non-clinical information related to the antiviral activity of Remdesivir against Omicron subvariants BF.7, BQ.1, XBB.1.5, CH.1.1. In addition, the MAH took the opportunity to implement editorial changes in the SmPC.” Opinion adopted on 09.11.2023.
Request for Supplementary Information adopted on 05.10.2023.

**Verzenios - Abemaciclib -**
**EMEA/H/C/004302/II/0028**
Eli Lilly Nederland B.V., Rapporteur: Filip Josephson, "Update of section 4.4 of the SmPC in order to add a new warning on "arterial thromboembolic events", based on a safety review. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to update section 9 of the SmPC.” Opinion adopted on 09.11.2023.

**Vipdomet - alogliptin / metformin -**
**EMEA/H/C/002654/II/0044**
Takeda Pharma A/S, Rapporteur: Patrick Vrijlandt, "Update of sections 4.4 and 4.8 of the SmPC in order to add a new warning on Vitamin B12 decrease or deficiency and to update the list of adverse drug reactions (ADRs) in accordance with the recent update of the PI for Glucophage, which is the reference label for the compound metformin, and following the request by MHRA on 20 June 2022 for all products containing metformin.” Opinion adopted on 26.10.2023.
**Xevudy - sotrovimab -**  
**EMEA/H/C/005676/II/0019/G**  
Glaxosmithkline Trading Services Limited,  
Rapporteur: Thalia Marie Estrup Blcher,  
“Update of sections 4.2, 4.8, 4.9, 5.1 and 5.2 of the SmPC in order to update posology recommendations and administration instructions as well as efficacy, pharmacokinetic and safety information, based on results from studies COMET-TAIL (phase 3 study and safety sub study; 217114), COMET-PEAK (216912), Japan-PK (217653) and BLAZE-4, and from a Population PK (PopPK) report. The MAH took the opportunity to add some editorial changes. The Package Leaflet is updated accordingly.”  

**Zavicefta - Ceftazidime / Avibactam -**  
**EMEA/H/C/004027/II/0033**  
Pfizer Ireland Pharmaceuticals, Rapporteur: Ingrid Wang, “Update of section 4.8 of the SmPC in order to add ‘Kounis syndrome’ to the list of adverse drug reactions (ADRs). The Package Leaflet is updated accordingly. In addition, the MAH is taking the opportunity to introduce minor changes to the PI and to update the list of local representatives in the Package Leaflet.”  
Request for Supplementary Information adopted on 09.11.2023.  

**WS2509/G**  
**Anoro Ellipta-**  
**EMEA/H/C/002751/WS2509/0042/G**  
**Laventair Ellipta-**  
**EMEA/H/C/003754/WS2509/0045/G**  
GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Finbarr Leacy, “Grouped application comprising two type II variations (C.I.4) as follows:  
- Update of section 4.8 of the SmPC in order to remove the duplication of ‘rash’ from the list of adverse drug reactions (ADRs) with frequency uncommon to align with a similar change previously accepted as part of the renewal procedure of Rolufta Ellipta.  
- To include significant changes to sections 2, 4.2, 4.4, 4.5, 4.8, 5.1, 5.2 and 6.5 of the SmPC,  
sections 3, 4, 5, 7 and 11 of the Labelling and sections 2, 3, 4, 5 and 6 of the Package Leaflet for the medicinal products Anoro and Laventair containing the active substances Umeclidinium Bromide and Vilanterol following the assessment of the medicinal products Trelegy and Rolufta Ellipta, which also contains the active substances fluticasone furoate, umecclidinium bromide and vilanterol, via procedure EMEA/H/C/004363/R/0023 and EMEA/H/C/004654/R/0019. The same wording is used for the combination product. The Package Leaflet and Labelling are updated accordingly. The Annex II is updated. In addition, the MAH took the opportunity to introduce minor editorial changes and to bring the PI in line with the latest QRD template (version 10.3)."

Request for Supplementary Information adopted on 09.11.2023.

WS2534
Abseamed-
EMEA/H/C/000727/WS2534/0104
Binocrit-
EMEA/H/C/000725/WS2534/0103
Epoetin alfa Hexal-
EMEA/H/C/000726/WS2534/0103
Sandoz GmbH, Lead Rapporteur: Alexandre Moreau, “Update of section 4.4 of the SmPC in order to allow for iron supplementation in accordance with patient needs and up-to-date treatment guidelines by removing the restrictions to exclusively use the oral route of administration for iron supplementation. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI, bring it in line with the latest QRD template version 10.3, align it with the reference product and update instructions for use.“
Request for Supplementary Information adopted on 31.08.2023.

WS2543
Imfinzi-EMEA/H/C/004771/WS2543/0062
IMJUDO-
EMEA/H/C/006016/WS2543/0003
AstraZeneca AB, Lead Rapporteur: Aaron Sosa Mejia, “Update of sections 4.2, 4.8, 5.1 and 5.2


Request for supplementary information adopted with a specific timetable.
of the SmPC in order to include paediatric information based on final results from study D419EC00001 “Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or Durvalumab in Combination with Tremelimumab in Pediatric Patients with Advanced Solid Tumors and Hematological Malignancies”. In addition, the MAH took this opportunity to introduce editorial changes.”

Request for Supplementary Information adopted on 09.11.2023.

### B.5.3. CHMP-PRAC assessed procedures

<table>
<thead>
<tr>
<th>Product Information</th>
<th>Positive Opinion adopted by consensus on</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Brineura - Cerliponase alfa</strong> - EMEA/H/C/004065/II/0039, Orphan BioMarin International Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Mari Thorn, “Update of sections 4.2, 4.4, 4.8, 5.1, 5.2, 6.5 and 9 of the SmPC in order to state that clinical data are available for patients aged 1 year and older and to include updates to the frequency of adverse reactions, immunogenicity, pharmacokinetic, and paediatric population sections based on the final results from studies 190-203, listed as a specific obligation and 190-202 (submitted in P46/013). Study 190-203 was a Phase 2, open-label, multicentre study in paediatric patients &lt; 18 years of age with CLN2 disease, confirmed by deficiency of TPP1 enzyme activity and mutation of the CLN2 gene. The Annex II.E and Package Leaflet are updated accordingly. The RMP version 4.0 has also been submitted.” Opinion adopted on 09.11.2023. Request for Supplementary Information adopted on 12.10.2023, 25.05.2023.</td>
<td>09.11.2023.</td>
</tr>
</tbody>
</table>

and final results from study C4591001, listed as a category 3 study in the RMP. This is a phase 1/2/3, placebo-controlled, randomised, observer-blind, dose-finding study to evaluate the safety, tolerability, immunogenicity, and efficacy of COMIRNATY against COVID-19 in healthy individuals.

C.I.11.b – Update of the RMP to version 11.0 in order to revise RMP milestones of final study reports of other on-going procedures, including other administrative and editorial changes.”

**Gavreto - pralsetinib** -  EMEA/H/C/005413/II/0012
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2, 4.4 and 4.5 of the SmPC in order to amend posology recommendations, warnings and drug-drug interaction information regarding the co-administration with CYP3A4 inhibitors, P-gp inhibitors and CYP3A4 inducers based on final results from the DDI study GP43162, listed as a category 3 study in the RMP, as well as results from the physiologically based pharmacokinetic (PBPK) analyses summarised in the PBPK Report 1120689. Study GP43162 is a phase 1, open-label, fixed-sequence study to evaluate the effect of a single dose of cyclosporine on the single dose pharmacokinetics of pralsetinib in healthy subjects. The RMP version 1.6 has also been submitted.”

Request for Supplementary Information adopted on 09.11.2023, 22.06.2023, 30.03.2023.

**Increlex - mecasermin** -  EMEA/H/C/000704/II/0080
Ipsen Pharma, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, “Update of sections 4.2, 4.6 and 4.8 of the SmPC in order to modify administration instructions recommendation regarding the monitoring of pre-prandial blood glucose in pre-prandial condition and in case of symptoms and to prevent the risk of lipohypertrophy, delete wording in the pregnancy section and update on number of patients with severe primary IGFD based on the cumulative review of safety database, scientific literature and clinical trials data. The Package Leaflet is updated.

accordingly. The RMP version 14.0 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet.\textquotedblleft; Opinion adopted on 26.10.2023. Request for Supplementary Information adopted on 31.08.2023.

**Lenvima - lenvatinib -**

**EMEA/H/C/003727/II/0050**

Eisai GmbH, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Ulla Wändel Liminga, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update paediatric information based on final results from studies E7080-G000-207 and E7080-G000-230. Study E7080-G000-207 is a multicenter, open-label, Phase 1/2 study of lenvatinib in children and adolescents with refractory or relapsed solid malignancies and young adults with osteosarcoma; Study E7080-G000-230 is a multicenter, open-label, randomized Phase 2 study to compare the efficacy and safety of lenvatinib in combination with ifosfamide and etoposide versus ifosfamide and etoposide in children, adolescents and young adults with Relapsed or Refractory Osteosarcoma (OLIE). The Package Leaflet is updated accordingly. The RMP version 15.1 has also been submitted.\textquotedblleft; Opinion adopted on 09.11.2023. Request for Supplementary Information adopted on 14.09.2023.

**Lumykras - sotorasib -**

**EMEA/H/C/005522/II/0007**

Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Update of sections 4.2 and 5.2 of the SmPC in order to update recommendations for patients with moderate to severe hepatic impairment following final results from study 20200362 listed as a category 3 PASS study in the EU RMP; this is a Phase I clinical study to evaluate the pharmacokinetics (PK) of a single oral dose of sotorasib administered in subjects with moderate or severe hepatic impairment compared with subjects who have normal hepatic function. The EU RMP version 1.0 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.3.\textquotedblright; Request for supplementary information adopted with a specific timetable.
### Myozyme - alglucosidase alfa -
**EMEA/H/C/000636/II/0095**
Sanofi B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Nathalie Gault, “Update of sections 4.4 and 5.2 of the SmPC in order to update a warning on immunogenicity. The RMP version 10.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

### Onglyza - saxagliptin -
**EMEA/H/C/001039/II/0057**
AstraZeneca AB, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update safety, efficacy and pharmacokinetic information in paediatric patients with Type 2 diabetes mellitus (T2DM) aged 10 to <18 years of age based on interim results from study D1680C00019 (T2NOW). This is a 26-week, multicentre, randomised, placebo-controlled, double-blind, parallel group, Phase III trial with a 26-week safety extension period evaluating the safety and efficacy of dапаглифозин (5 and 10 mg), and, separately, saxagliptin (2.5 and 5 mg) in paediatric patients with T2DM who were between 10 and below 18 years of age. The Package Leaflet is updated accordingly. The RMP version 17.1 has also been submitted. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template and to introduce editorial changes.”

### Pradaxa - Dabigatran etexilate -
**EMEA/H/C/000829/II/0147/G**
Boehringer Ingelheim International GmbH, Rapporteur: Thalia Marie Estrup Blicher, PRAC Rapporteur: Marie Louise Schougaard Christiansen, “A Grouped application consisting of:
C.I.7.a (type IB): to delete the pharmaceutical form "powder and solvent for oral solution, 6.25 mg/ml", as agreed in procedure
See 9.1
C.I.4 (type II): Update of section 4.1 of the SmPC in order to modify the indication following the deletion of the powder and solvent for oral solution; the Package Leaflet is updated accordingly. The RMP version 41.2 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI and update the list of local representatives in the Package Leaflet.


**Prolia - denosumab - EMEA/H/C/001120/II/0099**

Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Mari Thorn, “Update of sections 4.4 and 4.8 of the SmPC in order to update a warning regarding hypocalcaemia and to include reports of life-threatening events and fatal cases occurred in the post-marketing setting, particularly in patients with severe renal impairment, receiving dialysis or treatment with other calcium lowering drugs based on the cumulative review of the MAH safety database and literature. The Package Leaflet is updated accordingly. The RMP version 32.0 has also been submitted.”


**Reagila - cariprazine - EMEA/H/C/002770/II/0034**

Gedeon Richter Plc., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ana Sofia Diniz Martins, “Update of sections 4.3 and 4.5 of the SmPC in order to update an existing contraindication and update drug-drug interaction information with CYP3A4 inhibitors, based on final results from study RGH-188-301 (CYPRESS) listed as a category 3 study in the RMP; this is an open-label, single-arm, fixed-sequence study to investigate the effect of erythromycin, a moderate CYP3A4 inhibitor on the pharmacokinetics of cariprazine in male patients with schizophrenia. The Package Leaflet is updated accordingly. The RMP version 4.0 has also been submitted. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

Request for Supplementary Information adopted with a specific timetable.
**Tysabri - natalizumab -**  
**EMEA/H/C/000603/II/0136**  
Biogen Netherlands B.V., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Gabriele Maurer, "Update of sections 4.2 and 4.4 of the SmPC to modify administration instructions and update educational guidance to enable the subcutaneous formulation to be administered outside a clinical setting by healthcare professionals based on the cumulative review of post-marketing and clinical study data. The Package Leaflet and Annex IID are updated accordingly. The RMP version 29.1 has also been submitted. In addition, the MAH took this opportunity to introduce minor editorial changes."

**B.5.4. PRAC assessed procedures**

<table>
<thead>
<tr>
<th>PRAC Led</th>
<th>Request for supplementary information adopted with a specific timetable.</th>
</tr>
</thead>
</table>
| **Aldurazyme - laronidase -**  
**EMEA/H/C/000477/II/0085**  
Sanofi B.V., PRAC Rapporteur: Nathalie Gault, PRAC-CHMP liaison: Alexandre Moreau, "To update section 4.2 of the SmPC in order to modify the administration instructions following the assessment of procedure PSUSA/00001830/202104 based on literature review. The Package Leaflet is updated accordingly. The RMP version 1.0 has also been submitted.” Request for Supplementary Information adopted on 26.10.2023, 08.06.2023, 09.02.2023. |
| **Benlysta - belimumab -**  
**EMEA/H/C/002015/II/0116**  
GlaxoSmithKline (Ireland) Limited, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder, "Submission of the final report for the Belimumab Pregnancy registry (BEL114256) listed as a category 3 study in the RMP. This is a non-interventional study to evaluate pregnancy and infant outcomes for pregnancies in women with systemic lupus erythematosus (SLE) exposed to commercially supplied belimumab within the 4 months" |
| **EMA/CHMP/500954/2023**  
Page 29/60 |
preconception and/or during pregnancy. In addition, the BPR protocol planned to collect pregnancy and infant outcomes for pregnancies in women with SLE and SABLE (Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus) protocol who were not exposed to belimumab and enrolled in BPR. The RMP version 45.0 has also been submitted.”


PRAC Led
Evusheld - tixagevimab / cilgavimab - EMEA/H/C/005788/II/0013
AstraZeneca AB, PRAC Rapporteur: Kimmo Jaakkola, PRAC-CHMP liaison: Outi Mäki-Ikola,
“The RMP is updated to version 5.0 with the removal of the commitment to conduct the post-authorisation safety study (PASS) D8850R00006: A post-authorization Observational Study of Women exposed to EVUSHELD During Pregnancy (O-STEREO).”


Request for Supplementary Information adopted on 31.08.2023.

PRAC Led
Lenvima - lenvatinib - EMEA/H/C/003727/II/0053
Eisai GmbH, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder,
"Update of section 5.1 of the SmPC in order to update safety and efficacy information for the hepatocellular carcinoma (HCC) indication, based on interim results from study E7080-M000-508 (STELLAR), listed as a category 3 PASS in the RMP. This is a non-interventional multicentre, observational, phase 4 study to evaluate the safety and tolerability of lenvatinib in patients with advanced or unresectable HCC. RMP version 15.2 has also been submitted.”


PRAC Led
Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0093

Request for supplementary information adopted with a specific timetable.
|---|---|
| **PRAC Led**  
**Ozurdex - dexamethasone -**  
EMEA/H/C/001140/II/0044  
AbbVie Deutschland GmbH & Co. KG, PRAC  
Rapporteur: Maria del Pilar Rayon, PRAC-CHMP liaison: Maria Concepcion Prieto Yerro,  
"Submission of an updated RMP version 12.1.”  
Request for Supplementary Information adopted on 08.06.2023, 16.03.2023. |  
| **PRAC Led**  
**Remicade - infliximab -**  
EMEA/H/C/000240/II/0243  
Janssen Biologics B.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder,  
"To update section 4.8 of the SmPC to add weight increased to the list of adverse drug reactions (ADRs) with frequency Uncommon following PRAC PSUR assessment report (EMA/PRAC/158162/2023-Corr.1) based on the cumulative literature review. The Package Leaflet is updated accordingly. In addition, the MAH took this opportunity to introduce minor editorial changes.”  
| **PRAC Led**  
**Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) -**  
EMEA/H/C/005791/II/0110  
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Marie Louise Schougaard Christiansen, PRAC-CHMP liaison: Thalia Marie Estrup Blicher,  
"Submission of the final report of study P903 - US PASS (Post-authorisation safety in the US Study, NCT04958954), listed as a category 3 study in the RMP: Post-marketing safety of Spikevax vaccine in the US: Active surveillance, signal refinement and self-controlled risk interval (SCRI) signal evaluation in HealthVerity.”  
| **PRAC Led**  
**Tecfidera - dimethyl fumarate -**  
EMEA/H/C/002601/II/0082  
Weise, "Update of section 4.6 of the SmPC in order to update information on pregnancy based on results from study 109MS402 - Tecfidera (dimethyl fumarate) Pregnancy Exposure Registry, listed as a category 3 study in the RMP; This is an observational study and aims to address the safety concern of effects on pregnancy outcome and prospectively evaluates pregnancy outcomes in women with MS who were exposed to a Registry-specified Biogen MS product during the eligibility window for that product.

The Package Leaflet is updated accordingly. The RMP version 16.0 has also been approved. In addition, the MAH has taken the opportunity to introduce editorial changes to the Product Information."


Request for Supplementary Information adopted on 31.08.2023, 12.05.2023.

---

PRAC Led

**Xeljanz - tofacitinib -**

*EMEA/H/C/004214/II/0054*

Pfizer Europe MA EEIG, PRAC Rapporteur: Liana Gross-Martirosyan, PRAC-CHMP liaison: Peter Mol, "Submission of an updated RMP version 31.1 in order to modify study A3921427 from an interventional to a non-interventional study. In addition, the MAH has taken the opportunity to update other sections of the RMP."


Request for Supplementary Information adopted on 31.08.2023.

---

PRAC Led

**Zavesca - miglustat -**

*EMEA/H/C/000435/II/0076*

Janssen-Cilag International N.V., PRAC Rapporteur: Mari Thorn, PRAC-CHMP liaison: Kristina Dunder, "Update of section 4.4 of the SmPC with information regarding the fact that cases of Crohn’s disease have been reported post-marketing. The Package Leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement editorial changes in the SmPC and Package Leaflet, and to update the contact details of the local representatives in the Package Leaflet.

Submission of an updated RMP version 15.1 in order to remove risks in line with GVP module V

revision 2. The MAH has also taken the opportunity to introduce minor changes, such as update of the post-marketing exposure data and alignment with the latest Company EU-RMP Template."
Request for Supplementary Information adopted on 06.07.2023, 16.03.2023.

PRAC Led
WS2486
Emtricitabine/Tenofovir disoproxil Zentiva-EMEA/H/C/004137/WS2486/0025
Zentiva k.s., Generic, Generic of Truvada, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, PRAC-CHMP liaison: Bruno Sepodes, "C.I.11.z - To update the RMP for Emtricitabine/Tenofovir disoproxil according to reference product update, Truvada (EMEA/H/C/WS2320)."
Request for Supplementary Information adopted on 31.08.2023.

PRAC Led
WS2515
Lacosamide UCB-EMEA/H/C/005243/WS2515/0018
Vimpat-EMEA/H/C/000863/WS2515/0100
UCB Pharma S.A., Lead PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Filip Josephson, "Submission of an updated RMP version 17.0 in order to introduce new updates including the removal of category 3 study EP0158 due to study closure by lack of enrolment, and the removal of category 3 studies (SP848 and EP0034)."

PRAC Led
WS2519/G
Advagraf-EMEA/H/C/000712/WS2519/0071/G
Modigraf-EMEA/H/C/000954/WS2519/0046/G
Astellas Pharma Europe B.V., Lead PRAC Rapporteur: Eamon O Murchu, PRAC-CHMP liaison: Jayne Crowe, "A grouped application consisting of: Type II (C.I.13): Submission of the final report from study F506-PV-0001 listed as a category 3 study in the RMP for Advagraf and Modigraf. This is a non-interventional post-authorisation
safety study (NI-PASS) of outcomes associated with the use of tacrolimus around conception, or during pregnancy or lactation using data from Transplant Pregnancy Registry International (TPRI). The RMP version 5.0 has also been submitted.

Type IB (C.I.11.z): To include the feasibility assessment of using alternative secondary-use data sources to replicate the Transplant Pregnancy Registry International (TPRI) study as a category 3 additional pharmacovigilance activity in the RMP, including the milestones for the progress report and the final report of the feasibility assessment, related to EMEA/H/C/000712/MEA/032 and EMEA/H/C/000954/MEA/024.”


B.5.5. CHMP-CAT assessed procedures

**Carvykti - ciltaçabtagene autoleucel** - EMEA/H/C/005095/II/0018, Orphan, ATMP
Janssen-Cilag International NV, Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus

**Hemgenix - etranacogene dezaparvovec** - EMEA/H/C/004827/II/0009/G, Orphan, ATMP
CSL Behring GmbH, Rapporteur: Silke Dorner, CHMP Coordinator: Daniela Philadelphy

**Kymriah - tisagenlecleucel** - EMEA/H/C/004090/II/0071, Orphan, ATMP
Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang,
"Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTL019B2202 (a phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in pediatric patients with relapsed and refractory B-cell acute

Request for supplementary information adopted with a specific timetable.

lymphoblastic leukemia). Submission of cellular kinetic report for the B-cell acute lymphoblastic leukaemia (ALL) indication based on data from pivotal study CCT019B2202 and the supportive study CCT019B2205J involving paediatric ALL patients (partially fulfil REC). In addition, the MAH took this opportunity to introduce editorial changes.”

Roctavian - valoctocogene roxaparvovec - EMEA/H/C/005830/II/0008/G, Orphan, ATMP
BioMarin International Limited, Rapporteur: Violaine Closson Carella, CHMP Coordinator: Jean-Michel Race, “Grouped application comprising two variations as follows: C.I.4 - Update of section 4.5 of the SmPC in order to add drug-drug interaction information with Isotretinoin and Efavirenz based on results from study “In vitro Drug-Drug Interaction Study: Effects of Concomitant Administration of Isotretinoin, Amphetamine, Omeprazole, Celecoxib and Selected HAART Medications with AAV5-FVIII-SQ on Cytotoxicity and AAV5-FVIII-SQ DNA and RNA Expression in Primary Human Hepatocytes”. A.6 - To change the ATC Code from B02BD1 to “not yet assigned”.“ Opinion adopted on 09.11.2023, 31.10.2023.

Yescarta - axicabtagene ciloleucel - EMEA/H/C/004480/II/0063, Orphan, ATMP
Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, “Primary Analysis from study KTE-C19-107 (ZUMA-7); this is a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel versus standard of care therapy in subjects with relapsed/refractory diffuse large B cell lymphoma (DLBCL) in the 2nd line setting. In addition, the MAH took the opportunity to include the date of the latest renewal in section 9 and to submit a consolidated Environmental Risk Assessment (ERA) document.” Opinion adopted on 09.11.2023, 31.10.2023. Request for Supplementary Information adopted on 06.10.2023.
B.5.6. CHMP-PRAC-CAT assessed procedures

*Kymriah - tisagenlecleucel - EMEA/H/C/004090/II/0075, Orphan, ATMP*

Novartis Europharm Limited, Rapporteur: Rune Kjeken, CHMP Coordinator: Ingrid Wang,
"Update of sections 5.1 and 5.2 of the SmPC in order to update efficacy and pharmacokinetic information based on final results from study CCTLO19C2201 PAES in the Annex II (ANX008); this is a Phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The RMP version 6 has also been submitted. In addition, the MAH took the opportunity to update Annex II.D of the PI."

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

**WS2503/G**

Afstyla-
EMEA/H/C/004075/WS2503/0051/G

IDELVION-
EMEA/H/C/003955/WS2503/0067/G

Respreeza-
EMEA/H/C/002739/WS2503/0073/G

Voncento-
EMEA/H/C/002493/WS2503/0060/G

CSL Behring GmbH, Lead Rapporteur: Jan Mueller-Berghaus
Request for Supplementary Information adopted on 05.10.2023.

**WS2521**

Riltrava Aerosphere-
EMEA/H/C/005311/WS2521/0007

Trixeo Aerosphere-
EMEA/H/C/004983/WS2521/0014

AstraZeneca AB, Lead Rapporteur: Finbarr Leacy, "C.I.z - To submit the new results for the conducted fish full life-cycle study for budesonide and an updated Environmental Risk Assessment (ERA) report."
Request for Supplementary Information adopted on 31.08.2023.

WS2536
Rixathon-
EMEA/H/C/003903/WS2536/0067
Riximyo-
EMEA/H/C/004729/WS2536/0068
Sandoz GmbH, Lead Rapporteur: Jan Mueller-Berghaus

WS2576
Elebrato Ellipta-
EMEA/H/C/004781/WS2576/0037
Relvar Ellipta-
EMEA/H/C/002673/WS2576/0064
Revinty Ellipta-
EMEA/H/C/002745/WS2576/0061
Trelegy Ellipta-
EMEA/H/C/004363/WS2576/0034
GlaxoSmithKline (Ireland) Limited, Lead Rapporteur: Maria Concepcion Prieto Yerro
Request for Supplementary Information adopted on 09.11.2023.

WS2578
Fluenz Tetra-
EMEA/H/C/002617/WS2578/0133
Pandemic influenza vaccine H5N1
AstraZeneca-
EMEA/H/C/003963/WS2578/0067
AstraZeneca AB, Lead Rapporteur: Jan Mueller-Berghaus

WS2579/G
Fluenz Tetra-
EMEA/H/C/002617/WS2579/0134/G
Pandemic influenza vaccine H5N1
AstraZeneca-
EMEA/H/C/003963/WS2579/0068/G
AstraZeneca AB, Lead Rapporteur: Christophe Focke

WS2582
HyQvia-EMEA/H/C/002491/WS2582/0092
Kiovig-EMEA/H/C/000628/WS2582/0124
Takeda Manufacturing Austria AG, Lead Rapporteur: Jan Mueller-Berghaus

Request for supplementary information adopted with a specific timetable.
B.5.9. Information on withdrawn type II variation / WS procedure

<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA / Rapporteur</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mozobil - plerixafor - EMEA/H/C/001030/II/0051</td>
<td>Sanofi B.V., Rapporteur: Peter Mol, &quot;Update of section 4.6 of the SmPC in order to update information regarding duration of contraception after cessation of treatment; the Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to introduce a minor update to the Labelling section.”</td>
<td>The MAH withdrew the procedure on 18.10.2023.</td>
</tr>
<tr>
<td>Tremelimumab AstraZeneca - tremelimumab - EMEA/H/C/004650/II/0002</td>
<td>AstraZeneca AB, Rapporteur: Aaron Sosa Mejia, &quot;Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the paediatric information based on final results from study D419EC00001; this is a Phase I/II, open-label, multicenter study to evaluate the safety, tolerability, and preliminary efficacy of durvalumab monotherapy or durvalumab in combination with tremelimumab in pediatric patients with advanced solid tumors and</td>
<td>The MAH withdrew the procedure.</td>
</tr>
</tbody>
</table>
hematological malignancies.”

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

<table>
<thead>
<tr>
<th>Medicine</th>
<th>EMEA/H/C/Orphan</th>
<th>Status</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>guanfacine - EMEA/H/C/006312</td>
<td></td>
<td></td>
<td>treatment of ADHD</td>
</tr>
<tr>
<td>apremilast - EMEA/H/C/006193</td>
<td></td>
<td></td>
<td>treatment of psoriatic arthritis, psoriasis, Behçet’s disease</td>
</tr>
<tr>
<td>troriluzole - EMEA/H/C/006068, Orphan</td>
<td></td>
<td></td>
<td>Biohaven Bioscience Ireland Limited, is indicated for the treatment of adult patients with spinocerebellar ataxia genotype 3 (SCA3)</td>
</tr>
<tr>
<td>mirvetuximab soravtansine - EMEA/H/C/005036, Orphan</td>
<td></td>
<td></td>
<td>Immunogen Biopharma (Ireland) Limited, treatment of ovarian, fallopian tube, or primary peritoneal cancer</td>
</tr>
<tr>
<td>tiratricol - EMEA/H/C/005220, Orphan</td>
<td></td>
<td></td>
<td>Rare Thyroid Therapeutics International AB, treatment of monocarboxylate transporter 8 (MCT8) deficiency</td>
</tr>
<tr>
<td>eplontersen - EMEA/H/C/006295, Orphan</td>
<td></td>
<td></td>
<td>AstraZeneca AB, indicated for the treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis (ATTRv).</td>
</tr>
<tr>
<td>marstacimab - EMEA/H/C/006240, Orphan</td>
<td></td>
<td></td>
<td>Pfizer Europe Ma EEIG, Tradename is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A or haemophilia B</td>
</tr>
<tr>
<td>elafibranor - EMEA/H/C/006231, Orphan</td>
<td></td>
<td></td>
<td>Ipsen Pharma, treatment of primary biliary cholangitis (PBC)</td>
</tr>
<tr>
<td>sotatercept - EMEA/H/C/005647, Orphan</td>
<td></td>
<td>Accelerated review</td>
<td>Merck Sharp &amp; Dohme B.V., treatment of pulmonary arterial hypertension in adults</td>
</tr>
<tr>
<td>in vitro diagnostic medical device -</td>
<td></td>
<td></td>
<td>EMEA/H/D/006341, detection of the anaplastic lymphoma kinase</td>
</tr>
</tbody>
</table>
(ALK) protein

**clascoterone - EMEA/H/C/006138**
indicated for the topical treatment of acne vulgaris in adults and adolescents

**B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008: timetables for information**

**Mounjaro - tirzepatide -**
**EMEA/H/C/005620/X/0015**
Eli Lilly Nederland B.V., Rapporteur: Martina Weise, "Extension application to add 6 new strengths of 2.5 mg (4.17 mg/ml), 5 mg (8.33 mg/ml), 7.5 mg (12.5 mg/ml), 10 mg (16.67 mg/ml), 12.5 mg (20.83 mg/ml) and 15 mg (25 mg/ml) for Mounjaro solution for injection in pre-filled pen (KwikPen), multidose. The Package Leaflet and Labelling are updated in accordance."

**Ofev - nintedanib -**
**EMEA/H/C/003821/X/0057/G**
Boehringer Ingelheim International GmbH, Rapporteur: Finbarr Leacy, Co-Rapporteur: Ewa Balkowiec Iskra, PRAC Rapporteur: Nikica Mirošević Skvrce, "Extension application to add a new strength of 25 mg hard capsules, grouped with an extension of indication (C.I.6.a) to include treatment of fibrosing Interstitial Lung Diseases (ILDs) in children and adolescents from 6 to 17 years of age for Ofev, following the assessment of procedure X/0052/G, based on final results from study 1199-0337 (A Double Blind, Randomised, Placebo-controlled Trial to Evaluate the Dose-exposure and Safety of Nintedanib Per os on Top of Standard of Care for 24 Weeks, Followed by Open Label Treatment With Nintedanib of Variable Duration, in Children and Adolescents (6 to 17 Year-old) With Clinically Significant Fibrosing Interstitial Lung Disease), which is supplemented by the currently ongoing prospective Phase III extension trial 1199-0378 (An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 2 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease). The main objective of the study 1199-0337 was to evaluate dose-exposure and safety of nintedanib in children."
and adolescents with fibrosing Interstitial Lung Disease (ILD). As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and Labelling are updated in accordance. Version 12.0 of the RMP has also been submitted."

**Opsumit - macitentan -**
**EMEA/H/C/002697/X/0051/G, Orphan**

Janssen-Cilag International N.V., Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Maria del Pilar Rayon, “Extension application to introduce a new pharmaceutical form associated with new strengths (1 and 2.5 mg dispersible tablet) grouped with an extension of indication (C.I.6.a) to include, as monotherapy or in combination, the long-term treatment of pulmonary arterial hypertension (PAH) in paediatric patients aged 1 month to less than 18 years of age of WHO Functional Class (FC) I to III for OPSUMIT, based on interim results from AC-055-312 study (TOMORROW). This is a multicenter, open-label, randomized study with single-arm extension period to assess the pharmacokinetics, safety, and efficacy of macitentan versus standard of care in children with pulmonary arterial hypertension. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC for film-coated tablets are updated. The Package Leaflet and Labelling are updated in accordance. Version 14.1 of the RMP has also been submitted.”

**Ozempic - semaglutide -**
**EMEA/H/C/004174/X/0043**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt

**Rybelsus - semaglutide -**
**EMEA/H/C/004953/X/0038**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt, “Extension application to introduce three new strengths of tablets (1.5 mg, 4 mg and 9 mg) for semaglutide.”

**Rybelsus - semaglutide -**
**EMEA/H/C/004953/X/0039**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt, “Extension application to add two new strengths (25 mg and 50 mg) tablets.”

**Wegovy - semaglutide -**
**EMEA/H/C/005422/X/0016**
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

**apremilast - EMEA/H/C/006208**
treatment of psoriatic arthritis, psoriasis, Behçet’s disease

**aumolertinib - EMEA/H/C/006069**
treatment of non-small cell lung cancer
List of Questions adopted on 30.03.2023.

**buprenorphine - EMEA/H/C/006188**
treatment of opioid drug dependence
List of Questions adopted on 22.06.2023.

**sugemalimab - EMEA/H/C/006088**
treatment of adults with metastatic non-small-cell lung cancer (NSCLC)
List of Questions adopted on 22.06.2023.

**serplulimab - EMEA/H/C/006170, Orphan**
Henlius Europe GmbH, first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC)

**aprocitentan - EMEA/H/C/006080**
treatment of resistant hypertension
List of Questions adopted on 22.06.2023.

**omecamtiv mecarbil - EMEA/H/C/006112**
treatment of adult patients with symptomatic chronic heart failure and reduced ejection fraction less than 30%

**sotorasib - EMEA/H/C/005522/X/0009**
Amgen Europe B.V., Rapporteur: Alexandre Moreau, “Extension application to add a new strength of 240 mg film-coated tablet.”
List of Questions adopted on 22.06.2023.

**nintedanib - EMEA/H/C/006179**
treatment of idiopathic pulmonary fibrosis (IPF), chronic fibrosing interstitial lung diseases (ILDs) and lung diseases (ILDs) systemic sclerosis associated interstitial lung disease (SSc-ILD)

**nivolumab - EMEA/H/C/003985/X/0132**
Bristol-Myers Squibb Pharma EEIG, Rapporteur: Carolina Prieto Fernandez, PRAC Rapporteur:
Martin Huber

**in vitro diagnostic medical device - EMEA/H/D/006373**
detection of PD-L1 protein

**ustekinumab - EMEA/H/C/006183**
treatment of Crohn’s disease, Ulcerative colitis, Plaque psoriasis, Paediatric plaque psoriasis and Psoriatic arthritis (PsA)

**flortaucipir (18F) - EMEA/H/C/006064**
indicated for Positron Emission Tomography (PET) imaging of the brain

**teriflunomide - EMEA/H/C/005960/X/0002**
Accord Healthcare S.L.U., Generic, Generic of AUBAGIO, Rapporteur: Kristina Nadrah, PRAC Rapporteur: Martin Huber, "Extension application to add a new strength of 7 mg film-coated tablets. The bioequivalence study data were submitted."

**in vitro diagnostic medical device - EMEA/H/D/006310**
imunohistochemical assay utilising an anti-PD-L1 monoclonal primary antibody

**retifanlimab - EMEA/H/C/006194, Orphan**
Incyte Biosciences Distribution B.V., Treatment of Merkel cell carcinoma (MCC).

---

**B.6.4. Annual Re-assessments: timetables for adoption**

**Bylvay - odevixibat - EMEA/H/C/004691/S/0016, Orphan**
Albireo, Rapporteur: Patrick Vrijlandt, PRAC Rapporteur: Adam Przybylkowski

**Myalepta - metreleptin - EMEA/H/C/004218/S/0035, Orphan**
Amryt Pharmaceuticals DAC, Rapporteur: Karin Janssen van Doorn, PRAC Rapporteur: Adam
B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

**Cufence - trientine -**  
**EMEA/H/C/004111/R/0016**  
Univar Solutions BV, Rapporteur: Daniela Philadelphy, Co-Rapporteur: Konstantina Alexopoulou, PRAC Rapporteur: Ana Sofia Diniz Martins

**Deltyba - delamanid -**  
**EMEA/H/C/002552/R/0070, Orphan**  
Otsuka Novel Products GmbH, Rapporteur: Christophe Focke, PRAC Rapporteur: Jo Robays

**Dovato - dolutegravir / lamivudine -**  
**EMEA/H/C/004909/R/0045**  

**Giapreza - angiotensin II -**  
**EMEA/H/C/004930/R/0027**  
Paion Deutschland GmbH, Rapporteur: Maria Concepcion Prieto Yerro, Co-Rapporteur: Jean-Michel Race, PRAC Rapporteur: Menno van der Elst

**Jemperli - dostarlimab -**  
**EMEA/H/C/005204/R/0026**  

**LysaKare - L-lysine hydrochloride / L-arginine hydrochloride -**  
**EMEA/H/C/004541/R/0016**  
Advanced Accelerator Applications, Rapporteur: Janet Koenig, Co-Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Adam Przybylkowski

**Natpar - parathyroid hormone -**  
**EMEA/H/C/003861/R/0054, Orphan**  
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Karin Janssen van Doorn, Co-Rapporteur: Beata Maria Jakline
B.6.6. VARIATIONS – START OF THE PROCEDURE

Timetables for adoption provided that the validation has been completed.

B.6.7. Type II Variations scope of the Variations: Extension of indication

Amyvid - Florbetapir (18F) -
EMEA/H/C/002422/II/0046
Eli Lilly Nederland B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber,
"Extension of indication to include monitoring response to therapy for AMYVID, based on supporting literature. As a consequence, sections 4.1 and 4.4 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 5.1 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to update section 4.8 of the SmPC to reflect the current clinical trial exposures to align it with the updated RMP."

Dupixent - dupilumab -
EMEA/H/C/004390/II/0079
Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Finbarr Leacy, PRAC Rapporteur: Kimmo Jaakkola,
"Extension of indication for DUPIXENT to include treatment of adults as add-on maintenance treatment for uncontrolled chronic obstructive pulmonary disease (COPD) with type 2 inflammation on triple therapy or double therapy if inhaled corticosteroids (ICS) are contraindicated, based on final results from study EFC15804 (BOREAS); this is a phase 3, randomized, double blind, placebo-controlled, multi-center, parallel group, 52-week study to assess the efficacy, safety and tolerability of dupilumab in patients with moderate-to-severe chronic obstructive pulmonary disease (COPD) with type 2 inflammation. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 10.0 of the RMP has also been submitted."

Keytruda - pembrolizumab -
EMEA/H/C/003820/II/0145
Merck Sharp & Dohme B.V., Rapporteur: Paolo Gasparini, PRAC Rapporteur: Menno van der Elst, "Extension of indication to include in combination with chemoradiotherapy (external beam radiation therapy followed by brachytherapy) the treatment of high-risk locally advanced cervical cancer in adults who have not received prior definitive therapy [Stage IB2-IIb (with node-positive disease) or Stage III-IVA based on FIGO 2014] for Keytruda,"
Based on KEYNOTE-A18: A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer. As a consequence, sections 4.1 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 44.1 of the RMP has also been submitted.

Kinpeygo - budesonide -
EMEA/H/C/005653/II/0008, Orphan
STADA Arzneimittel AG, Rapporteur: Christian Gartner, PRAC Rapporteur: Marie Louise Schougaard Christiansen, "Extension of indication to slow kidney function decline in adults with primary immunoglobulin A (IgA) nephropathy (IgAN) for KINPEYGO, based on Part B of study NefIgArd (NEF-301), listed as the final specific obligation in the Annex II; this is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of oral Nefecon compared to matching placebo in patients with primary IgAN on a background of optimized RAS inhibitor therapy. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 1.1 of the RMP has also been submitted."

Opdivo - nivolumab -
EMEA/H/C/003985/II/0137
Bristol-Myers Squibb Pharma EEIG, Co-Rapporteur: Peter Mol, PRAC Rapporteur: Martin Huber, "Extension of indication to include in combination with cisplatin-based chemotherapy the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma for OPDIVO, based on interim results from study CA209901 (CheckMate901); this is a Phase 3, open-label, randomized study of nivolumab combined with ipilimumab, or with standard of care chemotherapy, versus standard of care chemotherapy in participants with previously untreated unresectable or metastatic urothelial cancer. As a consequence, sections 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 35.0 of the RMP has also been submitted."

RYBREVANT - amivantamab -
EMEA/H/C/005454/II/0010
Janssen-Cilag International N.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Gabriele Maurer, "Extension of indication to include amivantamab in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR) Exon 20 insertion mutations for RYBREVANT, based on the final results from study 61186372NSC3001 listed as a Specific Obligation in the Annex II of the Product Information; this is a global, open-label, randomized Phase 3 study of ACP compared to CP alone in participants with newly diagnosed, locally advanced or metastatic NSCLC characterized by EGFR exon 20ins. The primary objective of the PAPILLON study is to compare efficacy, as demonstrated by PFS, in participants treated with ACP versus CP alone. As a consequence, sections 4.1, 4.2, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.1 of the RMP has also been submitted. In addition, the MAH took the opportunity to update Annex II and Annex IV of the PI. Consequently, the MAH proposes a switch from marketing authorisation under exceptional circumstances to full marketing authorisation given the fulfilment of the SOB. As part of the application, the MAH also requests an extension of the market protection by one additional year."
Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

Triumeq - dolutegravir / abacavir / lamivudine - EMEA/H/C/002754/II/0116
ViiV Healthcare B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Martin Huber, "Extension of indication to include treatment of paediatric patients from 6 kg to less than 25 kg for Triumeq Dispersible Tablets, based on PK, safety and efficacy data observed in the final results of study 205860 (IMPAACT 2019), further supported by extrapolation to data generated in adults and additional data in paediatric patients with the single entities. IMPAACT 2019 is a Phase 1/2 open-label, multicenter, multiple dose study of dolutegravir/lamivudine/abacavir fixed dose
combination tablets in treatment-experienced and treatment-naïve HIV-1-infected children less than 12 years of age. As a consequence, sections 4.1, 4.2, 4.5, 4.8, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 22.0 of the RMP has also been submitted. In addition, the marketing authorisation holder (MAH) took the opportunity to introduce minor editorial changes to the PI.

**Wegovy - semaglutide -**

**EMEA/H/C/005422/II/0017**

Novo Nordisk A/S, Rapporteur: Patrick Vrijlandt, Co-Rapporteur: Thalia Marie Estrup Blicher, "Extension of indication to include risk reduction of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease and BMI ≥27 kg/m2 for WEGOVY, based on results from study EX9536-4388 (SELECT); this is a randomised, double-blind, placebo-controlled, trial comparing semaglutide 2.4 mg with placebo both administered s.c. once weekly in subjects with established cardiovascular disease and overweight or obesity. As a consequence, section 4.1, 4.2, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. As part of the application the MAH is requesting a 1-year extension of the market protection."

Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**WS2463**

**Imfinzi-EMEA/H/C/004771/WS2463/0063**

**Lynparza-EMEA/H/C/003726/WS2463/0066**

AstraZeneca AB, Lead Rapporteur: Carolina Prieto Fernandez, Lead PRAC Rapporteur: Amelia Cupelli, "Extension of indication for Lynparza in combination with Imfinzi for the maintenance treatment of adult patients with newly diagnosed advanced or recurrent endometrial cancer following treatment with Imfinzi and platinum-based chemotherapy, based on results from pivotal phase III study, D9311C00001 (DUO-E). This was a phase III, randomised, double-blind, placebo-controlled,
multicentre study evaluating the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 30 of the RMP has also been submitted.”

**WS2538**

**Braftovi**

**EMEA/H/C/004580/WS2538/0034**

**Mektovi**

**EMEA/H/C/004579/WS2538/0030**

Pierre Fabre Medicament, Lead Rapporteur: Janet Koenig, Lead PRAC Rapporteur: Rugile Pilvinienė, "Extension of indication to include binimetinib in combination with encorafenib for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with a BRAF V600 mutation for MEKTOVI and BRAFTOVI based on results from study PHAROS (study ARRAY-818-202) at the primary completion date; this is a Phase II, open-label, multicentre, non-comparative study (interventional). As a consequence, sections 4.1, 4.4, 4.8, 5.1, 5.2, 9 and 10 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 2.1 of the RMP has also been submitted. As part of the application, the MAH is requesting a 1-year extension of the market protection for Mektovi.” Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)

**B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects**

**Abiraterone Krka - abiraterone acetate -**

**EMEA/H/C/005649/II/0004**

KRKA, d.d., Novo mesto, Generic, Generic of Zytiga, Rapporteur: Andreja Kranjc

**Abrysvo - respiratory syncytial virus vaccine (bivalent, recombinant) -**

**EMEA/H/C/006027/II/0001**

Pfizer Europe Ma EEIG, Rapporteur: Jayne Crowe
<table>
<thead>
<tr>
<th>Drug Name</th>
<th>Summary</th>
<th>EMA Reference</th>
<th>Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bimzelx - bimekizumab</td>
<td>-</td>
<td>EMEA/H/C/005316/II/0023/G</td>
<td>UCB Pharma S.A., Rapporteur: Finbarr Leacy</td>
</tr>
<tr>
<td>Cerezyme - imiglucerase</td>
<td>-</td>
<td>EMEA/H/C/000157/II/0131</td>
<td>Sanofi B.V., Rapporteur: Patrick Vrijlandt</td>
</tr>
<tr>
<td>Kalydeco - ivacaftor</td>
<td>-</td>
<td>EMEA/H/C/002494/II/0120/G</td>
<td>Vertex Pharmaceuticals (Ireland) Limited, Rapporteur: Maria Concepcion Prieto Yerro</td>
</tr>
<tr>
<td>Keytruda - pembrolizumab</td>
<td>-</td>
<td>EMEA/H/C/003820/II/0144</td>
<td>Merck Sharp &amp; Dohme B.V., Rapporteur: Paolo Gasparini</td>
</tr>
<tr>
<td>Ryzodeg - insulin aspart / insulin degludec</td>
<td>-</td>
<td>EMEA/H/C/002499/II/0054</td>
<td>Novo Nordisk A/S, Rapporteur: Kristina Dunder</td>
</tr>
<tr>
<td>Suliqua - insulin glargine / lixisenatide</td>
<td>-</td>
<td>EMEA/H/C/004243/II/0037/G</td>
<td>Sanofi Winthrop Industrie, Rapporteur: Kristina Dunder</td>
</tr>
<tr>
<td>Tresiba - insulin degludec</td>
<td>-</td>
<td>EMEA/H/C/002498/II/0060</td>
<td>Novo Nordisk A/S, Rapporteur: Kristina Dunder</td>
</tr>
<tr>
<td>Trumenba - meningococcal group B vaccine</td>
<td>(recombinant, adsorbed)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>
EMEA/H/C/004051/II/0050/G
Pfizer Europe MA EEIG, Rapporteur: Patrick Vrijlandt

Zejula - niraparib -
EMEA/H/C/004249/II/0046/G, Orphan
GlaxoSmithKline (Ireland) Limited, Rapporteur: Ingrid Wang

WS2575
Dengue Tetravalent Vaccine (Live, Attenuated) Takeda-
EMEA/H/W/005362/WS2575/0009
Qdenga-
EMEA/H/C/005155/WS2575/0010
Takeda GmbH, Lead Rapporteur: Sol Ruiz

B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Alkindi - hydrocortisone -
EMEA/H/C/004416/II/0019
Diurnal Europe BV, Rapporteur: Karin Janssen van Doorn, "Update of section 4.2 of the SmPC in order to update posology recommendations in case of incomplete dosing, following the request by PRAC in the AR for procedure PSUSA/00010674/202208; the Package Leaflet is updated accordingly."

Drovelis - drospirenone / estetrol -
EMEA/H/C/005336/II/0021
Chemical Works of Gedeon Richter Plc. (Gedeon Richter Plc.), Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding hepatic impairment based on final results from study MIT-Do001-C102; this is a Phase 1, open-label, parallel group, single-dose study to evaluate the pharmacokinetics and safety of estetrol (E4) in subjects with varying degrees of hepatic function."

Dupixent - dupilumab -
EMEA/H/C/004390/II/0078
Sanofi Winthrop Industrie, Rapporteur: Jan Mueller-Berghaus, "Update of section 4.2 of the SmPC in order to allow the use of the Dupixent Prefilled Pen presentations for patients aged 2 to < 12 years of age based on final results of the R668-AD-1434 sub-study; this is an interventional open-label sub-study which purpose is to evaluate the PK, safety,
immunogenicity, and efficacy of repeat doses of dupilumab (200 mg Q4W, 300 mg Q4W, and 200 mg Q2W) administered SC using a PFP with a skin pinch in children ≥2 to <12 years of age. The Package Leaflet is updated accordingly. In addition, the MA took the opportunity to update the list of local representatives in the Package Leaflet.”

**Fetcroja - cefiderocol -**  
**EMEA/H/C/004829/II/0017**  
Shionogi B.V., Rapporteur: Filip Josephson, "Update of sections 4.5 and 5.2 of the SmPC in order to update drug-drug interaction information with CYP3A4 based on final results from study 2136R2118; this is a Phase 1, open-label, 1-sequence crossover, drug-drug interaction study to assess the effect of repeated doses of cefiderocol on the pharmacokinetics of midazolam in healthy adult participants.”

**Kesimpta - ofatumumab -**  
**EMEA/H/C/005410/II/0013/G**  
Novartis Ireland Limited, Rapporteur: Thalia Marie Estrup Blicher, "A grouped application consisting of:  
Type II (C.I.4): Update of sections 4.4 and 4.8 of the SmPC in order to amend an existing warning on injection-related reactions and to add ‘Hypersensitivity reactions’ to the list of adverse drug reactions (ADRs) with frequency not known. The Package Leaflet is updated accordingly.  
Type IB (C.I.z): Addition of a statement in the pre-filled syringes (PFS) instructions for use when PFS has been dropped on a hard surface.  
Type IA (A.6): To change the ATC Code of ofatumumab from L04AA52 to L04AG12. In addition, the MAH took the opportunity to introduce minor editorial changes to the PI.”

**Lydisilka - drospirenone / estetrol -**  
**EMEA/H/C/005382/II/0021**  
Estetra SRL, Duplicate, Duplicate of Drovelis, Rapporteur: Kristina Dunder, "Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding hepatic impairment based on final results from study MIT-Do001-C102; this is a Phase 1, open-label, parallel group, single-dose study to evaluate the pharmacokinetics and safety of estetrol (E4) in
subjects with varying degrees of hepatic function.”

Skilarence - dimethyl fumarate -
EMEA/H/C/002157/II/0034
Almirall S.A, Rapporteur: Janet Koenig, “Update of section 5.1 of the SmPC in order to update long-term efficacy and safety information based on final results from study M-41008-41 (Dimeskin 1); this is a phase IV non-randomised, non-interventional, open label study in adult patients with moderate to severe chronic plaque psoriasis to further assess long-term (12 months) efficacy and safety of Skilarence in routine daily practice in Spain.”

Spikevax - COVID-19 mRNA vaccine (nucleoside-modified) -
EMEA/H/C/005791/II/0114/G
Moderna Biotech Spain, S.L., Rapporteur: Jan Mueller-Berghaus, “Grouped application consisting of:
C.I.4 (Type II): Update of sections 4.4, 4.8 and 5.1 of the SmPC to update the safety information regarding the administration of Spikevax to individuals at least 18 years of age who have undergone solid orphan transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise, based on updated clinical literature and internal data; the Package Leaflet is updated accordingly.
C.I.2 (Type IB): To update section 6.6 of the SmPC in order to clarify the handling instructions for the pre-filled syringes; the Package Leaflet is updated accordingly.”

Translarna - ataluren -
EMEA/H/C/002720/II/0074, Orphan
PTC Therapeutics International Limited, Rapporteur: Peter Mol, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to change posology recommendations in the paediatric population, to update the summary of safety profile and to update efficacy, safety and pharmacokinetic information on the paediatric population based on the final results from study PTC124-GD-048-DMD “A Phase 2, multiple-dose, open-label study evaluating the safety and PK of ataluren in patients with nmDMD aged ≥6 months to <2 years old” (MEA-018). The Package Leaflet is updated accordingly. In
addition, the MAH took this opportunity to introduce editorial changes to the PI."

**Vaxelis - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and haemophilus type B conjugate vaccine (adsorbed) - EMEA/H/C/003982/II/0134**

MCM Vaccine B.V., Rapporteur: Christophe Focke, "Update of section 4.8 of the SmPC in order to add Extensive swelling of vaccinated limb to the list of adverse drug reactions (ADRs) with frequency rare and to update its description based on the cumulative review of clinical studies, literature and safety database. The Package Leaflet is updated accordingly."

**Vaxzevria - covid 19 vaccine (chadox1 s [recombinant]) - EMEA/H/C/005675/II/0095**

AstraZeneca AB, Rapporteur: Sol Ruiz, "Update of sections 4.1, 4.4 and 5.1 of the SmPC in order to update clinical information, following a critical evaluation of the benefit-risk profile of Vaxzevria against currently circulating variants of concern based on available data and structured benefit risk assessment."

**VidPrevtyn Beta - SARS-CoV-2, B.1.351 variant, prefusion Spike delta TM protein, recombinant - EMEA/H/C/005754/II/0007/G**

Sanofi Pasteur, Rapporteur: Jan Mueller-Berghaus, "A grouped application consisting of: Type II (C.I.4): Update of section 4.8 of the SmPC in order to include additional safety data based on safety update reports from studies VAT00008 booster extension and VAT00002 Cohort 2, in order to fulfil REC 20. Type IA (A.6): To change the ATC Code of the COVID-19 protein subunit vaccine from J07BX03 to J07BN04."

**Yselty - linzagolix choline - EMEA/H/C/005442/II/0010**

Theramex Ireland Limited, Rapporteur: Finbarr Leacy, "Submission of the final report from study PRIMROSE 3 (20-OBE2109-007), listed as a category 3 study in the RMP. This is a long-term follow-up study to assess bone mineral density in subjects with uterine fibroids completing the Phase 3 studies of linzagolix,"
PRIMROSE 1 or PRIMROSE 2.”

Ztalmy - ganaxolone -  
EMEA/H/C/005825/II/0002, Orphan  
Marinus Pharmaceuticals Emerald Limited,  
Rapporteur: Peter Mol, “Submission of the final report from study 1042-HME-1001 listed as post-authorisation measure (PAM) recommendation. This is an interventional Phase 1 Single Dose, Open-Label Crossover Comparative Bioavailability Study of Two Oral Formulations of Ganaxolone. The primary objective of this study was to evaluate and compare the pharmacokinetics of a new ganaxolone formulation with ganaxolone oral suspension after a single oral dose administration under fed conditions.”

B.6.10. CHMP-PRAC assessed procedures

Gavreto - pralsetinib -  
EMEA/H/C/005413/II/0017  
Roche Registration GmbH, Rapporteur: Aaron Sosa Mejia, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.2 and 5.2 of the SmPC in order to include information regarding moderate and severe hepatic impairment based on final results from study GP43163 listed as a category 3 study in the RMP; this is a Phase I, open-label, single-dose study to evaluate the pharmacokinetics and safety of pralsetinib in subjects with moderate or severe hepatic impairment compared to healthy subjects. The RMP version 1.8 has also been submitted. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet and to update the marketing authorisation renewal date in Annex I.”

Vpriv - velaglucerase alfa -  
EMEA/H/C/001249/II/0063  
Takeda Pharmaceuticals International AG Ireland Branch, Rapporteur: Martina Weise, PRAC Rapporteur: Martin Huber, “Update of section 4.2 of the SmPC in order to add information to support at-home self-administration of VPRIV by a trained patient and/or a caregiver based on post-marketing data and literature. The Package Leaflet and Annex IID are updated accordingly. The updated RMP version 13.0 has also been submitted.”
B.6.11. PRAC assessed procedures

PRAC Led

WS2569

Corlentor-

EMEA/H/C/000598/WS2569/0059

Ivabradine Anpharm-

EMEA/H/C/004187/WS2569/0019

Procoralan-

EMEA/H/C/000597/WS2569/0058

Les Laboratoires Servier, Lead PRAC
Rapporteur: Menno van der Elst, PRAC-CHMP
liaison: Patrick Vrijlandt, "C.I.11.z - To update the RMP to delete the obsolete products (Ivabradine Egis and Ivabradine Proterapia) that are still mentioned in the RMP."

B.6.12. CHMP-CAT assessed procedures

Breyanzi - lisocabtagene maraleucel / lisocabtagene maraleucel -

EMEA/H/C/004731/II/0032, ATMP

Bristol-Myers Squibb Pharma EEIG, Rapporteur: Concetta Quintarelli, CHMP Coordinator: Paolo Gasparini

Libmeldy - atidarsagene autotemcel -

EMEA/H/C/005321/II/0021, Orphan, ATMP

Orchard Therapeutics (Netherlands) B.V., Rapporteur: Emmely de Vries, CHMP Coordinator: Peter Mol

Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0039, Orphan, ATMP

Fondazione Telethon ETS, Rapporteur: Sol Ruiz, CHMP Coordinator: Maria Concepcion Prieto Yerro

Yescarta - axicabtagene ciloleucel -

EMEA/H/C/004480/II/0065, Orphan, ATMP

Kite Pharma EU B.V., Rapporteur: Jan Mueller-Berghaus, CHMP Coordinator: Jan Mueller-Berghaus, "Update of section 4.8 of the SmPC in order to add Infusion Related Reactions to the list of adverse drug reactions (ADRs) with frequency Common, based on a cumulative
review of the MAH safety database, clinical trials and post-marketing data. The Package Leaflet is updated accordingly.”

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

**WS2572/G**
Herceptin-
EMEA/H/C/000278/WS2572/0191/G
MabThera-
EMEA/H/C/000165/WS2572/0200/G
Roche Registration GmbH, Lead Rapporteur: Jan Mueller-Berghaus

**WS2581/G**
Fluenz Tetra-
EMEA/H/C/002617/WS2581/0136/G
Pandemic influenza vaccine H5N1
AstraZeneca-
EMEA/H/C/003963/WS2581/0070/G
AstraZeneca AB, Lead Rapporteur: Christophe Focke

**WS2589**
Ongentys-
EMEA/H/C/002790/WS2589/0062
Ontilyv-EMEA/H/C/005782/WS2589/0017
Bial - Portela & Cª, S.A., Lead Rapporteur: Martina Weise

**WS2592/G**
Nuwiq-
EMEA/H/C/002813/WS2592/0056/G
Vihuma-
EMEA/H/C/004459/WS2592/0038/G
Octapharma AB, Lead Rapporteur: Jan Mueller-Berghaus

**WS2602/G**
Eucreas-
EMEA/H/C/000807/WS2602/0104/G
Icandra-
EMEA/H/C/001050/WS2602/0109/G
Zomarist-
EMEA/H/C/001049/WS2602/0106/G
Novartis Europharm Limited, Lead Rapporteur:
B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)


B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.
E.1. PMF Certification Dossiers

E.1.1. Annual Update

E.1.2. Variations

E.1.3. Initial PMF Certification

E.2. Time Tables – starting & ongoing procedures: For information

PMF timetables starting and ongoing procedures Tabled in MMD and sent by post mail (folder E).

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.

G.2. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

H. ANNEX H - Product Shared Mailboxes – e-mail address